Introduction {#sec1}
============

Paclitaxel (Taxol), isolated from the bark of *Taxus brevifolia* Nutt in the late 1960s,^[@ref1]^ and its semisynthetic derivatives docetaxel (Taxotere) and cabazitaxel (Jevana) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) currently serve as the most widely used clinical antitumor drugs against breast cancer, ovarian cancer, non-small cell lung cancer, and prostate cancer, among various chemotherapeutic agents.^[@ref2]^ They are known to exert their therapeutic effect by their ability to accelerate the polymerization of tubulin and stabilize the resultant microtubules, which leads to apoptosis through a cell-signaling cascade.^[@ref3]−[@ref5]^ Because the significant role of taxoids in the field of anticancer and their undesirable side effects as well as drug resistance, numerous endeavors has been devoted to in-depth research on the structure--activity relationships (SARs) of paclitaxel to reveal the minimal structural requirements essential for biological activity and develop next-generation taxoid anticancer agents with better pharmacological properties and improved activity.^[@ref2],[@ref6],[@ref7]^ As a result of the SAR studies, the oxetane D-ring and unique C-13 side chains of paclitaxel were indispensable active groups,^[@ref8]−[@ref12]^ and it has been justified by a range of successful studies of paclitaxel mimics that the complex taxane skeleton was replaced by a structurally simplified core but retained part of the three-dimensional configuration and phenylisoserine side chain of paclitaxel.^[@ref13]−[@ref17]^

![Structures of paclitaxel, docetaxel, cabazitaxel, and abiraterone.](ao0c00558_0001){#fig1}

Currently, a good deal of bioactive taxoid mimics have resulted from modifications of the functional groups on the taxane baccatin core or modification of the size of the carbon rings contained within the molecule.^[@ref2]^ By contrast, less attention has been paid to the hybridization of paclitaxel with other biologically active natural products. In 2000, Wandless et al.^[@ref18]^ reported six paclitaxel--daunorubicin hybrids, and all of them displayed cytotoxic activity, although less than the parent monomers. In 2005, Guénard et al.^[@ref16]^ reported eight paclitaxel-steroidal hybrids bearing the phenylisoserine side chain to mimic "T-form" docetaxel. Their cytotoxicity against the KB cell line and MCF-7 cell line was not as excellent as that of docetaxel and did not show any inhibitory activity for microtubule disassembly. Although the above studies did not render any taxoid mimic with improved anticancer activity, they revealed that paclitaxel--natural product-based hybrids were potential agents which could be possibly extended and strengthen the medical utility of Taxol. Furthermore, the highly complex structure of paclitaxel, especially its baccatin component, prevents the large-scale production of synthetic paclitaxel, which makes paclitaxel prohibitively expensive. Therefore, the combination of the minimal pharmacophore of the taxoid (the C-13 phenylisoserine side chain) with other accessible taxane skeleton-like natural compounds to generate a baccatin-free compound with a taxane-like conformation which retains appreciable antitumor activity is necessary and exciting.

In our previous studies,^[@ref8]^ assays for antiproliferative activity indicated that paclitaxel mimics possessing only C-13 side chains and oxetane D-ring structures showed moderate antitumor activities. This result encouraged us to explore other paclitaxel mimics with both C-13 side chains and widely distributed paclitaxel-like natural skeletons. Kingston et al.^[@ref19]^ synthesized twelve steroid-linked Taxol analogues as potential anticancer drugs. They revealed that all conjugates were cytotoxic to the A2870 ovarian cancer cell line, although less so than Taxol. Inspired by this, we envisioned searching for more steroid analogues as the substituents of the baccatin core of Taxol. Dehydroepiandrosterone (DHEA) is a steroidal hormone which aids in the prevention of cancer in rodents. Studies show that low circulating levels of DHEA have been associated with a higher incidence of breast cancer in women.^[@ref20]^ In addition to its economical and accessible properties, the conformation and structure of DHEA are similar to those of taxane. Most important of all, abiraterone ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), formed by introducing a nitrogen heterocyclic ring into the D-ring of DHEA, has been used to treat cancer in clinic.^[@ref21]^ There may be potential advantages for hybrid molecules if both drugs can be deactivated as the result of linking function and then released together.^[@ref18]^ Accordingly, all the abovementioned benefits encourage us to synthesize paclitaxel--DHEA mimic hybrids to extend and strengthen the therapeutic use of paclitaxel for paclitaxel-resistant or paclitaxel-insensitive tumors. Herein, we reported the synthesis and in vitro anticancer activity of eighteen paclitaxel--DHEA hybrids, in which the intricate baccatin core is structurally replaced by DHEA analogues. In the synthesis strategy, the Suzuki--Miyaura reaction which is known for the formation of Csp^2^--Csp^2^ bonds was used as a key step to introduce different aromatic chains in the D-ring of DHEA to increase the diversity of this natural product. It is worth mentioning that this reaction is mainly used in the total synthesis of natural products;^[@ref22]−[@ref26]^ rare examples of direct modification of natural compounds with this reaction have been reported.^[@ref27],[@ref28]^

Results and Discussion {#sec2}
======================

Chemistry {#sec2.1}
---------

A series of novel hybrids consisting of DHEA mimic subunits have been designed and synthesized to replace the paclitaxel baccatin scaffold. The preparation of the hybrids is outlined in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}.

![Synthesis of the Designed Paclitaxel Hybrids **7a--7r**](ao0c00558_0002){#sch1}

Starting from DHEA, masking of the free hydroxy group as a silyl ether, followed by treatment with PhN(Tf)~2~ and potassium bis(trimethylsilyl)amide (KHMDS) at −78 °C, provided triflate **2**. Next, the famous Suzuki--Miyaura reaction which is widely used for the formation of Csp^2^--Csp^2^ bonds was carried out on the triflate **2** as a key step to cross-couple precursor **2** with boronic acid under the catalysis of PdCl~2~(PPh~3~)~2~ to access the targets **3a--3q**. After deprotection of the 3-TBS group, we focused on synthesizing the paclitaxel--DHEA hybrids. The DHEA analogues **4a--4q** were subjected to esterification with the purchased oxazolidinecarboxylic acids **5a** or **5b**,^[@ref29]^ which resulted in the formation of oxazolidinecarboxylate **6a--6r** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Treatment of the intermediates **6a--6r** with *p*-toluenesulfonic acid yielded eighteen paclitaxel--DHEA hybrids **7a--7r** in 60--85% yields.

Biological Activity Evaluation {#sec2.2}
------------------------------

The eighteen newly synthesized hybrids were evaluated in vitro for their anticancer activity against a human tumor cell line (HepG-2) by MTT assay. The most interesting results are presented in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. All the hybrids showed less anticancer activity than the positive control Taxol. Three ones (**7b**, **7g**, and **7i**) with ortho-substituents in the phenyl group of the D-ring of DHEA analogues indicated moderate anticancer activity, better than that of the others. Specifically, compound **7i** exhibited the best anticancer activity against cell line HepG-2 with an IC~50~ value of 26.39 μM.

###### Anticancer Activity Evaluation of Synthesized Hybrids

  compound   IC~50~ (μM) HepG-2   compound   IC~50~ (μM) HepG-2
  ---------- -------------------- ---------- --------------------
  **7a**     81.88                **7j**     \>300
  **7b**     35.23                **7k**     81.61
  **7c**     56.69                **7l**     153.66
  **7d**     73.37                **7m**     67.72
  **7e**     \>300                **7n**     128.86
  **7f**     69.35                **7o**     125.63
  **7g**     34.5                 **7p**     \>300
  **7h**     46.78                **7q**     \>300
  **7i**     26.39                **7r**     125.63
  Taxol      0.78                             

Conclusions {#sec3}
===========

To summarize, eighteen novel paclitaxel--DHEA hybrids were designed and synthesized according to the SARs of Taxol and our previous studies,^[@ref8]^ using the Suzuki--Miyaura reaction as a key step to directly introduce different aromatic chains in the D-ring of DHEA. The MTT assay showed all the hybrids displayed less anticancer activity than the positive control Taxol. Three ones (**7b**, **7g**, and **7i**) with ortho-substituents in the phenyl group of the D-ring of DHEA analogues indicated moderate anticancer activity, better than that of the others. The results may give inspiration and guide the following modification of paclitaxel-like hybrids with improved anticancer activity. The use of a baccatin-free hybrid component might be an effective strategy to establish a paclitaxel-based hybrid library.

Experimental Section {#sec4}
====================

Chemistry {#sec4.1}
---------

### Materials and General Method {#sec4.1.1}

Unless otherwise noted, the reagents are commercially available and used without further purification. Synthesized compounds were purified by chromatography on silica gel (200--300 mesh) purchased from Qingdao Haiyang Chemical Co., Ltd. NMR spectra were recorded on a Bruker AV 600 or 400 NMR spectrometer in CDCl~3~ with tetramethylsilane as the internal standard; chemical shifts (δ) were reported in ppm values and *J* in Hz. HR-ESI-MS data were measured using a Q-TOF micro mass spectrometer (Waters).

#### Preparation of Compound **1** {#sec4.1.1.1}

A solution of DHEA (10.4 mmol, 1.0 equiv), imidazole (31.2 mmol, 3.0 equiv), and 4-*N*-dimethylaminopyridine (1.04 mmol, 0.1 equiv) in dry dichloromethane (30 mL) was stirred at room temperature for 5 min. Then, *tert*-butyldimethylsilyl chloride (20.8 mmol, 2.0 equiv) was added to the mixed solution at 40 °C and the resultant mixture was stirred at the same temperature for 2 h until thin-layer chromatography showed complete consumption of the starting compound. Then, the reaction mixture was extracted with water and ethyl acetate (EtOAc) three times. The organic phase was washed with brine water and dried over Na~2~SO~4~. After removal of the solvent, the residue was purified by silica gel column chromatography (EtOAc/petroleum ether, 1:10) to afford compound **1** as a white solid in 90% yield. The ^1^H NMR data are consistent with the reported literature.^[@ref30]^

#### Preparation of Compound **2** {#sec4.1.1.2}

KHMDS \[0.5 M in tetrahydrofuran (THF), 3 mL, 1.5 mmol, 3.0 equiv\] was added to the mixture of compound **1** (0.5 mmol, 1.0 equiv) and PhN(Tf)~2~ (0.75 mmol, 1.5 equiv) in dry THF at −78 °C and the resultant mixture was stirred at the same temperature for 2 h and then neutralized with saturated NH~4~Cl (aq.). The mixture was extracted with EtOAc three times. The organic phase was washed with water and brine and dried over Na~2~SO~4~. After removal of the solvent, the crude mixture was purified by silica gel column chromatography (EtOAc/petroleum ether, 1:50) to afford the desired triflate **2** as a white solid, yield 65%. The ^1^H NMR data are consistent with the reported literature.^[@ref31]^

#### General Procedure for the Compounds **3a--3q** {#sec4.1.1.3}

A suspension of compound **2** (0.1 mmol, 1.0 equiv), boronic acid compound (0.1 mmol, 1 equiv), Na~2~CO~3~ (0.125 mmol, 1.25 equiv) and PdCl~2~(PPh~3~)~2~ (0.003 mmol, 0.03 equiv) in toluene (2 mL), EtOH (0.4 mL), and water (1 mL) was stirred at 75 °C under argon for 0.5 h. Then, the mixture was added to saturated NaHCO~3~ aq. (5.0 mL) and extracted with excess EtOAc three times. The organic phase was washed with water and brine and dried over Na~2~SO~4~. The solvent was removed and the crude mixture was purified by silica gel column chromatography (EtOAc/petroleum ether, 1:20) to obtain the desired compounds **3a--3q** as a white solid, yield 60--90%.

Compound **3a**, yield 60.0%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.00 (s, 2H), 6.89 (s, 1H), 5.88 (d, *J* = 1.2 Hz, 1H), 5.37 (d, *J* = 5.2 Hz, 1H), 3.76--3.25 (m, 1H), 2.31 (s, 6H), 2.31--2.16 (m, 3H), 2.13--1.98 (m, 3H), 1.87--1.34 (m, 11H), 1.07 (s, 3H), 1.06 (s, 3H), 0.91 (s, 9H), 0.08 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 155.1, 142.0, 137.6 × 2, 137.4, 128.6, 127.0, 124.7 × 2, 121.1, 72.8, 57.9, 50.7, 47.3, 43.0, 37.5, 36.9, 35.6, 32.2, 31.8, 31.7, 30.7, 26.1 × 3, 21.6 × 2, 21.1, 19.5, 18.4, 16.8, −4.4 × 2. HRMS (ESI) *m*/*z*: calcd for C~33~H~51~OSi^+^, 491.3704; found, 491.3766 M + H^+^.

Compound **3b**, yield 72%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.21--7.16 (m, 3H), 7.11--7.01 (m, 1H), 5.89 (dd, *J* = 3.1, 1.6 Hz, 1H), 5.39--5.33 (m, 1H), 3.57--3.43 (m, 1H), 2.34 (s, 3H), 2.31--2.16 (m, 3H), 2.13--2.00 (m, 3H), 1.86--1.42 (m, 11H), 1.06 (s, 3H), 1.05 (s, 3H), 0.90 (s, 9H), 0.07 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 155.1, 142.1, 137.7, 137.4, 128.1, 127.6, 127.6, 127.2, 123.9, 121.1, 72.8, 57.9, 50.7, 47.4, 43.0, 37.5, 36.9, 35.6, 32.2, 31.8, 31.7, 31.7, 30.6, 26.1 × 3, 21.1, 19.5, 18.2, 16.8, −4.4 × 2. HRMS (ESI) *m*/*z*: calcd for C~32~H~49~OSi^+^, 477.3547; found, 477.3550 M + H^+^.

Compound **3c**, yield 70%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.28 (d, *J* = 8.0 Hz, 2H), 7.11 (d, *J* = 8.0 Hz, 2H), 5.87 (s, 1H), 5.36 (d, *J* = 5.2 Hz, 1H), 3.56--3.44 (m, 1H), 2.34 (s, 3H), 2.32--2.16 (m, 3H), 2.12--1.97 (m, 3H), 1.85--1.22 (m, 11H), 1.07 (s, 3H), 1.09--1.03 (m, 3H, overlapped), 1.05 (s, 3H), 0.90 (s, 9H), 0.07 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 154.8, 142.0, 136.5, 134.6, 129.0 × 2, 126.7, 126.5 × 2, 121.1, 72.8, 57.8, 50.7, 47.3, 43.0, 37.5, 36.9, 35.6, 32.2, 31.8, 31.7, 30.6, 26.1 × 3, 21.3, 21.1, 19.5, 18.4, 16.7, −4.4 × 2. HRMS (ESI) *m*/*z*: calcd for C~32~H~49~OSi^+^, 477.3547; found, 477.3548 M + H^+^.

Compound **3d**, yield 79%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.77 (s, 2H), 7.72 (s, 1H), 6.11 (s, 1H), 5.39--5.33 (m, 1H), 3.54--3.44 (m, 1H), 2.35--2.24 (m, 2H), 2.24--2.16 (m, 1H), 2.14--1.98 (m, 3H), 1.86--1.42 (m, 11H), 1.07 (s, 3H), 1.07 (s, 3H), 0.89 (s, 9H), 0.06 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 152.6, 142.1, 139.5, 131.7, 131.4, 126.6 × 3, 124.9, 122.2, 120.9, 120.4, 72.7, 57.8, 50.3, 47.5, 43.0, 37.4, 36.9, 35.3, 32.2, 32.0, 31.6, 30.6, 26.1 × 3, 21.0, 19.5, 18.4, 16.8, −4.5 × 2. HRMS (ESI) *m*/*z*: calcd for C~33~H~45~F~6~OSi^+^, 599.3138; found, 599.3159 M + H^+^.

Compound **3e**, yield 75%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.38--7.28 (m, 2H), 6.98 (t, *J* = 8.8 Hz, 2H), 5.85 (d, *J* = 1.2 Hz, 1H), 5.39--5.33 (m, 1H), 3.57--3.36 (m, 1H), 2.36--2.16 (m, 3H), 2.11--1.99 (m, 3H), 1.85--1.37 (m, 11H), 1.06 (s, 3H), 1.03 (s, 3H), 0.90 (s, 9H), 0.07 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 163.2, 160.8, 154.0, 142.0, 133.6, 133.5, 128.4, 127.2, 121.1, 115.2, 114.9, 72.7, 57.8, 50.6, 47.3, 43.0, 37.5, 36.9, 35.5, 32.2, 31.7 × 2, 30.6, 26.1 × 3, 21.0, 19.5, 18.4, 16.7, −4.5 × 2. HRMS (ESI) *m*/*z*: calcd for C~32~H~46~F~3~OSi^+^, 531.3265; found, 531.3253 M + H^+^.

Compound **3f**, yield 90%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.32--7.23 (m, 4H), 5.91 (dd, *J* = 2.8, 1.6 Hz, 1H), 5.57--5.13 (m, 1H), 3.74--3.34 (m, 1H), 2.34--2.16 (m, 3H), 2.11--1.94 (m, 3H), 1.88--1.19 (m, 11H), 1.06 (s, 3H), 1.03 (s, 3H), 0.90 (s, 9H), 0.07 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 153.8, 142.0, 135.9, 132.6, 128.4 × 2, 128.1 × 2, 128.0, 121.0, 72.7, 57.8, 50.6, 47.3, 43.0, 37.4, 36.9, 35.5, 32.2, 31.8, 31.7, 30.6, 26.1 × 3, 21.0, 19.5, 18.4, 16.7, −4.5 × 2. HRMS (ESI) *m*/*z*: calcd for C~31~H~46~ClOSi^+^, 497.3001; found, 497.3018 M + H^+^.

Compound **3g**, yield 89%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.22 (t, *J* = 8.0 Hz, 1H), 6.95 (d, *J* = 8.0 Hz, 1H), 6.94--6.91 (m, 1H), 6.79 (dd, *J* = 8.4, 2.4 Hz, 1H), 5.95--5.91 (m, 1H), 5.39--5.34 (m, 1H), 3.81 (s, 3H), 3.56--3.46 (m, 1H), 2.37--2.16 (m, 3H), 2.15--1.96 (m, 3H), 1.87--1.33 (m, 11H), 1.07 (s, 3H), 1.06 (s, 3H), 0.90 (s, 9H), 0.07 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 159.5, 154.8, 142.0, 138.9, 129.1, 127.7, 121.1, 119.4, 112.7, 112.1, 72.7, 57.8, 55.3, 50.6, 47.4, 43.0, 37.4, 36.9, 35.6, 32.2, 31.7 × 2, 30.6, 26.1 × 3, 21.1, 19.5, 18.4, 16.8, −4.5 × 2. HRMS (ESI) *m*/*z*: calcd for C~32~H~49~O~2~Si^+^, 493.3496; found, 493.3508 M + H^+^.

Compound **3h**, yield 88%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.11--8.05 (m, 1H), 7.87--7.81 (m, 1H), 7.76 (d, *J* = 8.4 Hz, 1H), 7.49--7.41 (m, 3H), 7.27 (s, 1H), 5.77 (d, *J* = 1.2 Hz, 1H), 5.40 (d, *J* = 5.2 Hz, 1H), 3.56--3.45 (m, 1H), 2.45--2.08 (m, 5H), 1.85--1.68 (m, 5H), 1.62--1.40 (m, 6H), 1.05 (s, 3H), 1.01 (s, 3H), 0.91 (s, 9H), 0.08 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 152.9, 142.1, 136.1, 133.9, 133.0, 129.8, 128.2, 127.1, 126.9, 125.7, 125.6, 125.5, 125.0, 121.1, 72.7, 57.7, 50.9, 49.7, 43.0, 37.5, 37.0, 35.3, 32.5, 32.2, 31.9, 31.1, 26.1 × 3, 21.0, 19.5, 18.4, 16.4, −4.4 × 2. HRMS (ESI) *m*/*z*: calcd for C~35~H~48~OSiH^+^, 513.3547; found, 513.3556 M + H^+^.

Compound **3i**, yield 65%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.21 (t, *J* = 2.0 Hz, 1H), 8.07 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.68 (d, *J* = 8.0 Hz, 1H), 7.46 (d, *J* = 8.0 Hz, 1H), 6.08 (dd, *J* = 3.2, 1.2 Hz, 1H), 5.39--5.33 (m, 1H), 3.56--3.40 (m, 1H), 2.36--2.15 (m, 3H), 2.13--2.00 (m, 3H), 1.87--1.36 (m, 11H), 1.08 (s, 3H), 1.07 (s, 3H), 0.89 (s, 9H), 0.06 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 152.9, 148.4, 142.1, 139.1, 132.7, 130.5, 129.2, 121.6, 121.5, 120.9, 72.7, 57.8, 50.5, 47.5, 43.0, 37.4, 36.9, 35.4, 32.2, 31.9, 31.7, 30.6, 26.1 × 3, 21.0, 19.5, 18.4, 16.8, −4.4 × 2. HRMS (ESI) *m*/*z*: calcd for C~31~H~46~NO~3~Si^+^, 508.3241; found, 508.3260 M + H^+^.

Compound **3j**, yield 77%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.38 (d, *J* = 8.0 Hz, 2H), 7.32--7.20 (m, 3H), 5.92 (dd, *J* = 2.8, 1.6 Hz, 1H), 5.38--5.35 (m, 1H), 3.55--3.45 (m, 1H), 2.35--2.14 (m, 3H), 2.13--1.99 (m, 3H), 1.86--1.41 (m, 11H), 1.07 (s, 3H), 1.06 (s, 3H), 0.90 (s, 9H), 0.07 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 154.9, 142.0, 137.5, 128.2 × 2, 127.4, 126.8 × 3, 121.1, 72.7, 57.9, 50.7, 47.4, 43.0, 37.5, 36.9, 35.5, 32.2, 31.8, 31.8, 30.6, 26.1 × 3, 21.1, 19.5, 18.4, 16.8, −4.4 × 2. HRMS (ESI) *m*/*z*: calcd for C~31~H~47~OSi^+^, 463.3391; found, 463.3387 M + H^+^.

Compound **3k**, yield 76%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.18 (d, *J* = 2.4 Hz, 1H), 7.74 (td, *J* = 8.4, 2.4 Hz, 1H), 6.86 (dd, *J* = 8.4, 3.2 Hz, 1H), 5.94 (dd, *J* = 3.2, 1.6 Hz, 1H), 5.37--5.32 (m, 1H), 3.53--3.43 (m, 1H), 2.34--2.14 (m, 3H), 2.09--1.92 (m, 3H), 1.84--1.32 (m, 11H), 1.05 (s, 3H), 1.01 (s, 3H), 0.89 (s, 9H), 0.06 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 163.9/161.5, 150.7, 145.4/145.3, 142.0, 139.3/139.2, 131.2/131.1, 129.4, 120.9, 109.1/108.8, 72.7, 57.7, 50.5, 47.5, 43.0, 37.4, 36.9, 35.4, 32.2, 31.9, 31.7, 30.6, 26.1 × 3, 21.0, 19.5, 18.4, 16.6, −4.4 × 2. HRMS (ESI) *m*/*z*: calcd for C~30~H~45~FNOSi^+^, 482.3249; found, 482.3253 M + H^+^.

Compound **3l**, yield 88%:^1^H NMR (400 MHz, CDCl~3~): δ 8.40 (d, *J* = 2.4 Hz, 1H), 7.64 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.29 (d, *J* = 4.4 Hz, 1H), 6.03 (dd, *J* = 3.2, 1.6 Hz, 1H), 5.40--5.35 (m, 1H), 3.57--3.46 (m, 1H), 2.37--2.17 (m, 3H), 2.13--1.96 (m, 3H), 1.90--1.24 (m, 11H), 1.08 (s, 3H), 1.04 (s, 3H), 0.92 (s, 9H), 0.09 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 150.6, 149.6, 147.7, 142.0, 136.6, 132.0, 130.2, 123.8, 120.9, 72.7, 57.7, 50.5, 47.5, 43.0, 37.4, 36.9, 35.3, 32.2, 32.0, 31.6, 30.5, 26.1 × 3, 21.0, 19.45, 18.4, 16.7, −4.5 × 2. HRMS (ESI) *m*/*z*: calcd for C~30~H~45~ClNOSi^+^, 498.2953; found, 498.2963 M + H^+^.

Compound **3m**, yield 68%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.17 (d, *J* = 2.0 Hz, 1H), 7.58 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.69 (d, *J* = 8.5 Hz, 1H), 5.85 (s, 1H), 5.35 (d, *J* = 5.2 Hz, 1H), 3.93 (s, 3H), 3.55--3.42 (m, 1H), 2.34--2.14 (m, 3H), 2.03 (dt, *J* = 4.4, 3.0 Hz, 3H), 1.85--1.33 (m, 11H), 1.05 (s, 3H), 1.00 (s, 3H), 0.89 (s, 9H), 0.06 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 163.2, 151.6, 144.4, 142.1, 137.4, 127.1, 126.5, 121.0, 110.4, 72.7, 57.7, 53.5, 50.6, 47.4, 43.0, 37.4, 36.9, 35.5, 32.2, 31.8, 31.7, 30.6, 26.1 × 3, 21.0, 19.5, 18.4, 16.6, −4.5 × 2. HRMS (ESI) *m*/*z*: calcd for C~31~H~48~NO~2~Si^+^, 494.3349; found, 494.3360 M + H^+^.

Compound **3n**, yield 75%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.61 (d, *J* = 1.6 Hz, 1H), 8.51--8.22 (m, 1H), 7.66 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.22 (dd, *J* = 8.0, 4.8 Hz, 1H), 5.99 (d, *J* = 1.2 Hz, 1H), 5.46--5.25 (m, 1H), 3.49 (ddd, *J* = 15.6, 10.8, 4.8 Hz, 1H), 2.37--2.14 (m, 3H), 2.11--1.98 (m, 3H), 1.85--1.32 (m, 11H), 1.06 (s, 3H), 1.04 (s, 3H), 0.89 (s, 9H), 0.06 (s, 6H). HRMS (ESI) *m*/*z*: calcd for C~30~H~46~NOSi^+^, 464.3343; found, 464.3346 M + H^+^. The ^1^H NMR data is consistent with literature.^[@ref32]^

Compound **3o**, yield 65%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.49 (d, *J* = 6.4 Hz, 2H), 7.27--7.22 (m, 2H), 6.16 (dd, *J* = 3.2, 1.6 Hz, 1H), 5.37--5.32 (m, 1H), 3.53--3.43 (m, 1H), 2.33--2.15 (m, 3H), 2.15--1.99 (m, 3H), 1.84--1.40 (m, 9H), 1.10--0.99 (m, 2H, overlapped), 1.06 (s, 3H, overlapped), 1.06 (s, 3H, overlapped), 0.89 (s, 9H), 0.06 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 152.6, 149.8 × 2, 144.7, 142.1, 131.6, 121.3 × 2, 120.9, 72.7, 57.7, 50.5, 47.3, 43.0, 37.4, 36.9, 35.3, 32.2, 32.0, 31.6, 30.5, 26.1 × 3, 21.0, 19.5, 18.4, 16.7, −4.5 × 2. HRMS (ESI) *m*/*z*: calcd for C~30~H~46~NOSi^+^, 464.3343; found, 464.3352 M + H^+^.

Compound **3p**, yield 66%: ^1^H NMR (400 MHz, CDCl~3~): δ 5.63 (dd, *J* = 2.8, 1.6 Hz, 1H), 5.35 (d, *J* = 5.2 Hz, 1H), 3.56--3.43 (m, 1H), 2.29 (s, 3H), 2.35--2.16 (m, 3H, overlapped), 2.16 (s, 3H), 2.13--1.98 (m, 2H), 1.83--1.46 (m, 12H), 1.03 (s, 3H), 0.89 (s, 9H), 0.82 (s, 3H), 0.06 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 165.7, 159.9, 144.4, 142.0, 132.5, 120.9, 112.5, 72.7, 56.9, 50.8, 49.5, 43.0, 37.4, 37.0, 35.4, 32.3, 32.2, 31.8, 30.9, 26.1 × 3, 20.9, 19.5, 18.4, 16.4, 12.1, 11.2, −4.5 × 2. HRMS (ESI) *m*/*z*: calcd for C~30~H~48~NO~2~Si^+^, 482.3449; found, 482.3466 M + H^+^.

Compound **3q**, yield 78%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.16--7.12 (m, 1H), 7.04 (d, *J* = 3.6 Hz, 1H), 6.97 (dd, *J* = 5.2, 3.6 Hz, 1H), 5.98 (dd, *J* = 2.8, 2.0 Hz, 1H), 5.38--5.33 (m, 1H), 3.57--3.42 (m, 1H), 2.38--2.15 (m, 4H), 2.03 (ddd, *J* = 16.0, 10.8, 3.0 Hz, 2H), 1.87--1.36 (m, 11H), 1.07 (s, 3H), 1.03 (s, 3H), 0.90 (s, 9H), 0.07 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 148.2, 142.0, 140.1, 127.3, 126.8, 123.6, 122.9, 121.0, 72.7, 57.4, 50.7, 47.8, 43.0, 37.4, 36.9, 35.6, 32.2, 31.8, 31.7, 30.6, 26.1 × 3, 21.1, 19.5, 18.4, 16.4, −4.4 × 2. HRMS (ESI) *m*/*z*: calcd for C~29~H~45~OSSi^+^, 469.2995; found, 469.3008 M + H^+^.

#### General Procedure for the Compounds **4a--4q** {#sec4.1.1.4}

The solution of compound **3** (0.05 mmol, 1.0 equiv) and tetrabutylammonium fluoride (0.06 mmol, 1.2 equiv) in THF (10 mL) was stirred at 80 °C overnight. The mixture was neutralized with saturated NH~4~Cl (aq.) and the resultant mixture was extracted with EtOAc three times. The organic phase was washed with water and brine and dried over Na~2~SO~4~. The solvent was removed and the crude mixture was purified by silica gel column chromatography (EtOAc/petroleum ether, 1:4) to afford the desired compounds **4a--4q** as a white solid, yield 86--95%.

Compound **4a**, yield 88%: ^1^H NMR (400 MHz, CDCl~3~): δ 6.99 (s, 2H), 6.88 (s, 1H), 5.88 (dd, *J* = 2.8, 1.6 Hz, 1H), 5.40 (d, *J* = 5.1 Hz, 1H), 3.61--3.46 (m, 1H), 2.38--2.32 (m, 1H), 2.31 (s, 6H), 2.27--2.15 (m, 2H), 2.15--1.97 (m, 3H), 1.90--1.38 (m, 11H), 1.07 (s, 3H), 1.06 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 155.1, 141.2, 137.6 × 2, 137.4, 128.6, 127.0, 124.7 × 2, 121.7, 71.9, 57.8, 50.6, 47.3, 42.5, 37.3, 36.8, 35.6, 31.8, 31.7, 31.6, 30.6, 21.6 × 2, 21.1, 19.5, 16.81. HRMS (ESI) *m*/*z*: calcd for C~27~H~37~O^+^, 377.2839; found, 377.2822 M + H^+^.

Compound **4b**, yield 95%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.22--7.14 (m, 3H), 7.08--7.02 (m, 1H), 5.90 (dd, *J* = 3.2, 1.6 Hz, 1H), 5.42--5.36 (m, 1H), 3.60--3.46 (m, 1H), 2.35 (s, 3H), 2.32--2.17 (m, 3H), 2.13--1.98 (m, 3H), 1.90--1.41 (m, 11H), 1.07 (s, 3H), 1.06 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 155.0, 141.2, 137.7, 137.4, 128.1, 127.6 × 2, 127.2, 123.9, 121.6, 71.9, 57.8, 50.6, 47.3, 42.4, 37.3, 36.8, 35.5, 31.8, 31.7, 31.7, 30.6, 21.7, 21.1, 19.5, 16.8. HRMS (ESI) *m*/*z*: calcd for C~26~H~35~O^+^, 363.2682; found, 363.2658 M + H^+^.

Compound **4c**, yield 94%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.28 (d, *J* = 8.0 Hz, 2H), 7.11 (d, *J* = 8.0 Hz, 2H), 5.87 (dd, *J* = 3.2, 1.6 Hz, 1H), 5.42--5.37 (m, 1H), 3.54 (m, 1H), 2.33 (s, 3H), 2.31--2.17 (m, 3H), 2.12--1.97 (m, 3H), 1.90--1.45 (m, 11H), 1.07 (s, 3H), 1.05 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 154.6, 141.1, 136.4, 134.4, 128.8 × 2, 126.6 × 2, 126.4, 121.5, 71.8, 57.7, 50.4, 47.1, 42.3, 37.2, 36.7, 35.4, 31.7, 31.6, 31.6, 30.5, 21.1, 21.0, 19.4, 16.6. HRMS (ESI) *m*/*z*: calcd for C~26~H~35~O^+^, 363.2682; found, 363.2673 M + H^+^.

Compound **4d**, yield 91%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.77 (s, 2H), 7.72 (s, 1H), 6.11 (dd, *J* = 3.2, 2.0 Hz, 1H), 5.41--5.37 (m, 1H), 3.59--3.47 (m, 1H), 2.38--2.19 (m, 3H), 2.15--1.99 (m, 3H), 1.89--1.45 (m, 11H), 1.08 (s, 6H). ^13^C NMR (100 MHz, CDCl~3~): δ 152.5, 141.3, 139.4, 131.7, 131.4, 131.3, 126.6, 126.6, 124.9, 122.2, 121.4, 120.4, 71.8, 57.8, 50.4, 47.5, 42.4, 37.3, 36.8, 35.3, 32.0, 31.8, 31.6, 30.5, 21.0, 19.5, 16.8. HRMS (ESI) *m*/*z*: calcd for C~27~H~31~F~6~O^+^, 485.2274; found, 485.2255 M + H^+^.

Compound **4e**, yield 86%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.36--7.28 (m, 2H), 6.98 (t, *J* = 8.4 Hz, 2H), 5.85 (s, 1H), 5.39 (d, *J* = 4.6 Hz, 1H), 3.60--3.54 (m, 1H), 2.37--2.16 (m, 3H), 2.11--1.97 (m, 3H), 1.90--1.39 (m, 11H), 1.07 (s, 3H), 1.03 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 163.1/160.7, 153.8, 141.1, 133.4, 133.4, 128.3, 128.2, 127.1, 121.5, 115.0, 114.8, 71.8, 57.6, 50.4, 47.2, 42.3, 37.2, 36.7, 35.4, 31.7, 31.6, 31.6, 30.5, 20.9, 19.4, 16.6. HRMS (ESI) *m*/*z*: calcd for C~26~H~32~F~3~O^+^, 417.2400; found, 417.2413 M + H^+^.

Compound **4f**, yield 89%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.34--7.23 (m, 4H), 5.93 (dd, *J* = 3.2, 1.6 Hz, 1H), 5.43--5.38 (m, 1H), 3.61--3.49 (m, 1H), 2.40--2.18 (m, 3H), 2.13--1.99 (m, 3H), 1.92--1.39 (m, 11H), 1.08 (s, 3H), 1.05 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 153.8, 141.2, 135.9, 132.6, 128.4 × 2, 128.1 × 2, 128.0, 121.6, 71.9, 57.8, 50.5, 47.3, 42.4, 37.3, 36.8, 35.4, 31.8 × 2, 31.7, 30.6, 21.0, 19.5, 16.7. HRMS (ESI) *m*/*z*: calcd for C~25~H~32~ClO^+^, 383.2136; found, 383.2143 M + H^+^.

Compound **4g**, yield 89%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.22 (t, *J* = 8.0 Hz, 1H), 6.97 (d, *J* = 7.6 Hz, 1H), 6.93--6.90 (m, 1H), 6.78 (dd, *J* = 8.0, 2.4 Hz, 1H), 5.93 (dd, *J* = 3.1, 1.7 Hz, 1H), 5.93 (dd, *J* = 3.2, 2.0 Hz, 1H), 5.41--5.37 (m, 1H), 3.81 (s, 3H), 3.46--3.59 (m, 1H), 2.37--2.18 (m, 3H), 2.13--1.97 (m, 3H), 1.88--1.46 (m, 11H), 1.07 (s, 3H), 1.05 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 159.5, 154.8, 141.3, 138.9, 129.2, 127.7, 121.6, 119.4, 112.7, 112.1, 71.9, 57.8, 55.3, 50.6, 47.4, 42.5, 37.3, 36.8, 35.6, 31.8, 31.7, 31.7, 30.6, 27.7, 21.1, 19.5, 16.8. HRMS (ESI) *m*/*z*: calcd for C~26~H~35~O~2~^+^, 379.2632; found, 379.2645 M + H^+^.

Compound **4h**, yield 94%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.10--8.05 (m, 1H), 7.86--7.80 (m, 1H), 7.76 (d, *J* = 8.4 Hz, 1H), 7.49--7.41 (m, 3H), 7.26 (d, *J* = 7.2 Hz, 1H), 5.77 (dd, *J* = 2.8, 1.2 Hz, 1H), 5.43 (d, *J* = 5.2 Hz, 1H), 3.60--3.49 (m, 1H), 2.45--2.09 (m, 5H), 1.88--1.70 (m, 6H), 1.67--1.41 (m, 7H), 1.06 (s, 3H), 1.01 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 152.8, 141.3, 136.1, 133.9, 133.0, 129.8, 128.2, 127.1, 126.9, 125.7 × 2, 125.5, 125.0, 121.6, 71.9, 57.6, 50.8, 49.7, 42.5, 37.3, 36.9, 35.2, 32.4, 31.9, 31.8, 31.1, 21.0, 19.5, 16.4. HRMS (ESI) *m*/*z*: calcd for C~29~H~35~O^+^, 399.2682; found, 399.2676 M + H^+^.

Compound **4i**, yield 90%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.21 (t, *J* = 1.6 Hz, 1H), 8.07 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.68 (d, *J* = 7.6 Hz, 1H), 7.45 (t, *J* = 8.0 Hz, 1H), 6.08 (dd, *J* = 3.2, 1.6 Hz, 1H), 5.42--5.37 (m, 1H), 3.60--3.46 (m, 1H), 2.39--2.19 (m, 3H), 2.14--2.01 (m, 3H), 1.91--1.35 (m, 11H), 1.08 (s, 3H), 1.07 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 152.9, 148.4, 141.3, 139.1, 132.7, 130.5, 129.1, 121.5, 121.5 × 2, 71.8, 57.8, 50.4, 47.5, 42.4, 37.3, 36.8, 35.3, 31.9, 31.8, 31.6, 30.5, 21.0, 19.5, 16.8. HRMS (ESI) *m*/*z*: calcd for C~25~H~32~NO~3~^+^, 394.2377; found, 394.2386 M + H^+^.

Compound **4j**, yield 89%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.41--7.34 (m, 2H), 7.33--7.19 (m, 3H), 5.92 (dd, *J* = 3.2, 1.6 Hz, 1H), 5.43--5.36 (m, 1H), 3.53 (m, 1H), 2.38--2.17 (m, 3H), 2.16--1.94 (m, 3H), 1.94--1.45 (m, 11H), 1.07 (s, 3H), 1.06 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 154.9, 141.2, 137.5, 128.2 × 2, 127.4, 126.8, 126.8 × 2, 121.6, 71.9, 57.8, 50.5, 47.3, 42.4, 37.3, 36.8, 35.5, 31.8, 31.7, 31.7, 30.6, 21.1, 19.5, 16.8. HRMS (ESI) *m*/*z*: calcd for C~25~H~32~OH^+^, 349.2526; found, 349.2545 M + H^+^.

Compound **4k**, yield 94%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.19 (d, *J* = 2.0 Hz, 1H), 7.74 (td, *J* = 8.4, 2.4 Hz, 1H), 6.86 (dd, *J* = 8.4, 2.8 Hz, 1H), 5.94 (dd, *J* = 2.8, 1.6 Hz, 1H), 5.42--5.36 (m, 1H), 3.59--3.48 (m, 1H), 2.36--2.20 (m, 3H), 2.11--1.91 (m, 3H), 1.89--1.39 (m, 11H), 1.06 (s, 3H), 1.01 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 163.9/161.3, 150.7, 145.4/145.3, 141.3, 139.3/139.3, 131.2/131.1, 129.4, 121.4, 109.2/108.8, 71.8, 57.6, 50.5, 47.5, 42.4, 37.3, 36.8, 35.4, 31.9, 31.7, 31.6, 30.6, 21.0, 19.5, 16.6. HRMS (ESI) *m*/*z*: calcd for C~24~H~31~FNO^+^, 368.2384; found, 368.2398 M + H^+^.

Compound **4l**, yield 94%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.40 (d, *J* = 2.4 Hz, 1H), 7.63 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.28 (d, *J* = 2.8 Hz, 1H), 6.03 (dd, *J* = 3.2, 1.6 Hz, 1H), 5.44--5.38 (m, 1H), 3.62--3.50 (m, 1H), 2.45--2.22 (m, 3H), 2.14--1.96 (m, 3H), 1.91--1.42 (m, 11H), 1.09 (s, 3H), 1.05 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 150.6, 149.6, 147.6, 141.3, 136.7, 132.2, 130.0, 123.8, 121.4, 71.8, 57.6, 50.4, 47.5, 42.4, 37.3, 36.8, 35.3, 32.0, 31.7, 31.6, 30.5, 21.0, 19.5, 16.7. HRMS (ESI) *m*/*z*: calcd for C~24~H~30~ClNOH^+^, 384.2089; found, 384.2103 M + H^+^.

Compound **4m**, yield 95%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.17 (d, *J* = 2.0 Hz, 1H), 7.57 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.68 (d, *J* = 8.4 Hz, 1H), 5.85 (dd, *J* = 2.8, 1.6 Hz, 1H), 5.42--5.35 (m, 1H), 3.92 (s, 3H), 3.58--3.47 (m, 1H), 2.26 (m, 3H), 2.10--1.97 (m, 3H), 1.88--1.36 (m, 11H), 1.06 (s, 3H), 1.01 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 163.1, 151.5, 144.4, 141.3, 137.4, 127.1, 126.4, 121.5, 110.4, 71.8, 57.6, 53.5, 50.5, 47.3, 42.4, 37.3, 36.8, 35.5, 31.7 × 2, 31.6, 30.6, 21.0, 19.5, 16.6. HRMS (ESI) *m*/*z*: calcd for C~25~H~34~NO~2~^+^, 380.2584; found, 380.2588 M + H^+^.

Compound **4n**, yield 91%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.62 (d, *J* = 2.0 Hz, 1H), 8.46 (dd, *J* = 4.8, 1.6 Hz, 1H), 7.65 (dt, *J* = 8.0, 2.0 Hz, 1H), 7.25--7.18 (m, 1H), 6.00 (dd, *J* = 3.2, 1.6 Hz, 1H), 5.42--5.36 (m, 1H), 3.61--3.48 (m, 1H), 2.39--2.20 (m, 3H), 2.06 (m, 3H), 1.90--1.39 (m, 11H), 1.07 (s, 3H), 1.05 (s, 3H). HRMS (ESI) *m*/*z*: calcd for C~24~H~32~NO^+^, 350.2478; found, 350.2489 M + H^+^. The ^1^H NMR data is consistent with the reported literature.^[@ref33]^

Compound **4o**, yield 94%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.49 (dd, *J* = 4.8, 1.6 Hz, 2H), 7.28--7.23 (m, 2H), 6.17 (dd, *J* = 3.2, 2.0 Hz, 1H), 5.41--5.35 (m, 1H), 3.59--3.45 (m, 1H), 2.37--2.21 (m, 3H), 2.16--2.00 (m, 3H), 1.91--1.39 (m, 11H), 1.07 (s, 6H). HRMS (ESI) *m*/*z*: calcd for C~24~H~31~NOH^+^, 350.2478; found, 350.2489 M + H^+^. The ^1^H NMR data is consistent with the reported literature.^[@ref33]^

Compound **4p**, yield 91%: ^1^H NMR (400 MHz, CDCl~3~): δ 5.64 (d, *J* = 1.2 Hz, 1H), 5.38 (d, *J* = 4.8 Hz, 1H), 3.58--3.47 (m, 1H), 2.35--2.28 (m, 1H, overlapped), 2.29 (s, 3H), 2.28--2.25 (m, 1H), 2.15 (s, 3H), 2.10--1.97 (m, 2H), 1.90--1.77 (m, 2H), 1.76--1.19 (m, 11H), 1.04 (s, 3H), 0.82 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 165.7, 159.8, 144.3, 141.3, 132.5, 121.4, 112.5, 71.8, 56.9, 50.7, 49.5, 42.4, 37.3, 36.9, 35.4, 32.3, 31.7, 31.7, 30.9, 21.0, 19.5, 16.4, 12.0, 11.2. HRMS (ESI) *m*/*z*: calcd for C~24~H~34~NO~2~^+^, 368.2584; found, 368.2596 M + H^+^.

Compound **4q**, yield 92%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.14 (d, *J* = 4.8 Hz, 1H), 7.03 (d, *J* = 3.6 Hz, 1H), 6.97 (dd, *J* = 5.2, 3.6 Hz, 1H), 5.98 (dd, *J* = 3.2, 2.0 Hz, 1H), 5.40--5.36 (m, 1H), 3.60--3.46 (m, 1H), 2.37--2.20 (m, 3H), 2.11--1.98 (m, 3H), 1.90--1.37 (m, 11H), 1.07 (s, 3H), 1.03 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 148.2, 141.2, 140.1, 127.3, 126.8, 123.6, 122.9, 121.6, 71.9, 57.3, 50.6, 47.8, 42.5, 37.3, 36.8, 35.6, 32.3, 31.8 × 2, 31.6, 30.6, 21.1, 19.5, 16.4. HRMS (ESI) *m*/*z*: calcd for C~23~H~31~OS^+^, 355.2090; found, 355.2093 M + H^+^.

#### General Procedure for Compounds **6a--6r** {#sec4.1.1.5}

A suspension of compound **4** (0.1 mmol, 1.0 equiv), oxazolidinecarboxylic acids **5a** or **5b** (0.12 mmol, 1.2 equiv), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.12 mmol, 1.2 equiv), and 4-(dimethylamino) pyridine (0.1 mmol, 1.0 equiv) in toluene (5 mL) was stirred at 80 °C for 18 h and then quenched with HCl (1 M). The mixture was added to a saturated solution of NaHCO~3~ (aq.) to adjust the mixture to pH 7 and then the mixture was extracted with EtOAc three times. The organic layer was treated with aqueous HCl (1 M), a saturated solution of NaHCO~3~ (aq.), and then brine, and each washing was performed at least three times. The organic layer was washed with 5% NaHCO~3~ liquid (3 × 15 mL) and dried over Na~2~SO~4~. The residue was purified by silica gel column chromatography (EtOAc/petroleum ether, 1:15) to afford the corresponding compounds **6a--6r** as a white solid, yield 46--88%.

Compound **6a**, yield 82%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.60--7.12 (m, 13H), 7.02 (s, 2H), 6.91 (s, 1H), 6.87 (d, *J* = 8.8 Hz, 2H), 5.98 (dd, *J* = 2.8, 1.6 Hz, 1H), 5.48 (d, *J* = 4.4 Hz, 1H), 5.47--5.34 (m, 1H, overlapped), 4.87 (br s, 1H), 4.84--4.73 (m, 1H), 3.85 (s, 3H), 2.42 (d, *J* = 8.0 Hz, 2H), 2.34 (s, 6H), 2.25 (ddd, *J* = 16.0, 6.4, 3.2 Hz, 1H), 2.17--1.99 (m, 3H), 1.94--1.86 (m, 2H), 1.84--1.41 (m, 9H), 1.12 (s, 3H), 1.09 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.7, 160.0, 155.0, 139.6, 137.6, 137.4, 135.8, 130.8, 130.2, 128.9, 128.8, 128.6, 128.4, 128.1, 127.2, 127.0, 124.7, 123.1, 113.6, 75.9, 57.7, 55.4, 50.4, 47.3, 38.1, 36.9, 36.9, 35.5, 31.7, 31.7, 30.6, 30.3, 27.7, 21.6 × 2, 21.0, 19.4, 16.8. HRMS (ESI) *m*/*z*: calcd for C~51~H~56~NO~5~^+^, 762.4153; found, 762.4156 M + H^+^.

Compound **6b**, yield 85%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.40--7.15 (m, 15H), 7.07--7.02 (m, 1H), 7.00--6.74 (m, 3H), 5.90 (d, *J* = 1.2 Hz, 1H), 5.45 (d, *J* = 4.4 Hz, 1H), 5.45--5.30 (m, 1H, overlapped), 4.90 (br s, 1H), 4.80--4.69 (m, 1H), 3.81 (s, 3H), 2.39 (d, *J* = 8.0 Hz, 2H), 2.34 (s, 3H), 2.23 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.13--1.97 (m, 3H), 1.93--1.85 (m, 2H), 1.82--1.43 (m, 9H), 1.09 (s, 3H), 1.06 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.7, 160.0, 155.0, 139.6, 137.7, 137.4, 135.8, 130.7, 130.2, 128.9, 128.8, 128.4, 128.1, 128.1, 127.6, 127.2, 127.1, 123.9, 123.1, 113.6, 75.9, 57.7, 55.4, 50.4, 47.3, 38.1, 36.9, 36.9, 35.5, 31.7, 31.7, 30.6, 27.7, 21.7, 21.0, 19.4, 16.8. HRMS (ESI) *m*/*z*: calcd for C~50~H~54~NO~5~^+^, 748.3997; found, 748.3976 M + H^+^.

Compound **6c**, yield 76%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.49--7.22 (m, 14H), 7.14 (d, *J* = 8.0 Hz, 2H), 6.99--6.76 (m, 3H), 5.90 (dd, *J* = 2.8, 1.6 Hz, 1H), 5.48 (d, *J* = 4.4 Hz, 1H), 5.48--5.34 (m, 1H, overlapped), 4.86 (br s, 1H), 4.83--4.72 (m, 1H), 3.84 (s, 3H), 2.42 (d, *J* = 8.0 Hz, 2H), 2.36 (s, 3H), 2.25 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.16--1.99 (m, 4H), 1.96--1.88 (m, 2H), 1.84--1.44 (m 8H), 1.11 (s, 3H), 1.08 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.7, 160.0, 154.7, 139.5, 136.5, 135.8, 134.5, 130.7, 130.2, 128.9, 128.9, 128.8, 128.7, 128.3, 128.1, 127.2, 126.7, 126.5, 123.1, 113.6, 75.9, 57.6, 55.4, 50.4, 47.2, 38.1, 36.9, 36.9, 35.5, 31.7, 31.6, 31.0, 30.5, 27.7, 21.3, 21.0, 19.4, 16.7. HRMS (ESI) *m*/*z*: calcd for C~50~H~54~NO~5~^+^, 748.3997; found, 748.3977 M + H^+^.

Compound **6d**, yield 83%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.78 (s, 2H), 7.73 (s, 1H), 7.38--7.19 (m, 12H), 6.99--6.76 (m, 3H), 6.12 (d, *J* = 1.2 Hz, 1H), 5.46 (d, *J* = 4.2 Hz, 1H), 5.46--5.31 (m, 1H, overlapped), 4.84 (br s, 1H), 4.79--4.72 (m, 1H), 3.82 (s, 3H), 2.40 (d, *J* = 8.0 Hz, 2H), 2.31 (ddd, *J* = 16.0, 6.4, 3.2 Hz, 1H), 2.14--2.01 (m, 3H), 1.93--1.86 (m, 2H), 1.84--1.46 (m, 9H), 1.10 (s, 3H), 1.09 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.7, 160.0, 152.5, 139.6, 139.4, 135.8, 131.7, 131.4, 131.3, 130.8, 130.2, 128.9, 128.8, 128.4, 128.1, 127.2, 126.6, 126.6, 124.9, 122.9, 122.2, 120.4, 120.4, 119.5, 113.6, 75.8, 57.7, 55.4, 50.3, 47.5, 38.0, 36.9, 36.9, 35.2, 31.9, 31.6, 31.6, 30.5, 27.7, 20.9, 19.4, 16.8. HRMS (ESI) *m*/*z*: calcd for C~51~H~50~F~6~NO~5~^+^, 870.3588; found, 870.3609 M + H^+^.

Compound **6e**, yield 46%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.44--7.17 (m, 10H), 7.27--7.17 (m, 4H), 6.97 (t, *J* = 8.8 Hz, 3H), 6.84 (d, *J* = 7.2 Hz, 2H), 5.88--5.82 (m, 1H), 5.45 (d, *J* = 4.4 Hz, 1H), 5.46--5.31 (m, 1H, overlapped), 4.84 (br s, 1H), 4.80--4.71 (m, 1H), 3.80 (s, 3H), 2.40 (d, *J* = 8.0 Hz, 2H), 2.22 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.13--2.04 (m, 3H), 1.92--1.85 (m, 2H), 1.81--1.40 (m, 9H), 1.09 (s, 3H), 1.03 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.6, 163.2, 160.7, 159.9, 153.8, 139.5, 135.7, 133.4, 133.4, 130.7, 130.1, 128.8, 128.7, 128.3, 128.3, 128.2, 128.1, 127.1, 123.0, 115.1, 114.9, 113.5, 75.8, 57.6, 55.3, 50.3, 47.2, 38.0, 36.9, 36.8, 36.8, 35.3, 31.6, 31.6, 30.5, 27.7, 20.9, 19.3, 16.6. HRMS (ESI) *m*/*z*: calcd for C~50~H~51~F~3~NO~5~^+^, 802.3714; found, 802.3726 M + H^+^.

Compound **6f**, yield 80%:^1^H NMR (400 MHz, CDCl~3~): δ 7.42--7.22 (m, 16H), 7.02--6.81 (m, 3H), 5.94 (dd, *J* = 3.2, 1.6 Hz, 1H), 5.48 (d, *J* = 4.0 Hz, 1H), 5.48--5.31 (m, 1H, overlapped), 4.86 (s, 1H), 4.82--4.72 (m, 1H), 3.84 (s, 3H), 2.42 (d, *J* = 7.6 Hz, 2H), 2.26 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.16--2.00 (m, 3H), 1.95--1.87 (m, 2H), 1.84--1.73 (m, 2H), 1.73--1.42 (m, 7H), 1.11 (s, 3H), 1.07 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.7, 160.0, 153.8, 139.6, 135.8, 132.6, 130.8, 130.2, 128.9, 128.8, 128.4, 128.3, 128.1, 128.0, 128.0, 127.2, 123.0, 113.6, 75.8, 57.7, 55.4, 50.4, 47.3, 38.1, 36.9, 36.9, 36.9, 35.4, 31.7, 31.7, 30.5, 27.7, 21.0, 19.4, 16.7. HRMS (ESI) *m*/*z*: calcd for C~49~H~51~ClNO~5~^+^, 768.3450; found, 768.3469 M + H^+^.

Compound **6g**, yield 66%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.49--7.16 (m, 14H), 6.97 (d, *J* = 8.0 Hz, 1H), 6.93--6.91 (m, 1H), 6.85 (d, *J* = 7.2 Hz, 2H), 6.79 (dd, *J* = 8.4, 2.0 Hz, 1H), 5.93 (dd, *J* = 2.8, 1.6 Hz, 1H), 5.45 (d, *J* = 4.4 Hz, 1H), 5.46--5.31 (m, 1H, overlapped), 4.84 (s, 1 H), 4.80--4.70 (m, 1H), 3.81 (s, 3H, overlapped), 3.81 (s, 3H, overlapped), 2.39 (d, *J* = 7.6 Hz, 2H), 2.23 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.15--1.97 (m, 3H), 1.93--1.83 (m, 2H), 1.81--1.42 (m, 9H), 1.09 (s, 3H), 1.06 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.7, 160.0, 159.4, 154.7, 139.6, 138.8, 135.8, 130.7, 130.2, 129.1, 128.9, 128.7, 128.3, 128.1, 127.6, 127.2, 126.8, 123.1, 119.4, 113.6, 112.7, 112.0, 75.8, 57.7, 55.4, 55.3, 50.4, 47.3, 38.0, 36.9, 36.9, 35.5, 31.8, 31.7, 31.7, 30.9, 27.6, 20.9, 19.3, 16.3. HRMS (ESI) *m*/*z*: calcd for C~50~H~54~NO~6~^+^, 764.3946; found, 764.3932 M + H^+^.

Compound **6h**, yield 60%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.15--8.08 (m, 1H), 7.90--7.83 (m, 1H), 7.80 (d, *J* = 8.4 Hz, 1H), 7.53--7.43 (m, 4H), 7.43--7.23 (m, 12H), 7.05--6.77 (m, 3H), 5.81 (d, *J* = 1.6 Hz, 1H), 5.52 (d, *J* = 4.4 Hz, 1H), 5.52--5.31 (m, 1H, overlapped), 4.88 (br s, 1H), 4.85--4.75 (m, 1H), 3.85 (s, 3H), 2.49--2.39 (m, 3H), 2.31--2.14 (m, 2H), 1.93--1.75 (m, 5H), 1.72--1.43 (m, 7H), 1.11 (s, 3H), 1.05 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.6, 159.9, 152.7, 139.5, 136.0, 135.7, 133.8, 132.9, 130.7, 130.1, 129.7, 128.8, 128.7, 128.3, 128.1, 128.0, 127.1, 127.0, 126.8, 125.6, 125.5, 125.0, 123.0, 113.5, 75.8, 57.3, 55.3, 50.5, 49.6, 38.0, 36.9, 36.8, 35.0, 32.3, 31.8, 31.8, 30.9, 27.6, 20.9, 19.3, 16.3. HRMS (ESI) *m*/*z*: calcd for C~53~H~54~NO~5~^+^, 784.3997; found, 784.4021 M + H^+^.

Compound **6i**, yield 78%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.22 (s, 1H), 8.08 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.69 (d, *J* = 7.6 Hz, 1H), 7.57--7.17 (m, 13H), 7.01--6.75 (m, 3H), 6.09 (d, *J* = 1.2 Hz, 1H), 5.46 (d, *J* = 4.0 Hz, 1H), 5.52--5.20 (m, 1H, overlapped), 4.84 (br s, 1H), 4.81--4.70 (m, 1H), 3.82 (s, 3H), 2.40 (d, *J* = 7.6 Hz, 2H), 2.30 (ddd, *J* = 15.6, 6.4, 2.4 Hz, 1H), 2.14--2.02 (m, 3H), 1.94--1.37 (m, 11H), 1.10 (s, 3H, overlapped), 1.09 (s, 3H, overlapped). ^13^C NMR (100 MHz, CDCl~3~): δ 169.7, 160.0, 152.8, 148.4, 139.6, 139.0, 135.8, 132.7, 130.7, 130.4, 130.2, 129.1, 128.9, 128.8, 128.3, 128.1, 127.2 × 4, 122.9, 121.6, 121.4, 113.6, 75.8, 57.6, 55.4, 50.3, 47.4, 38.0, 36.9, 36.9, 35.2, 31.9, 31.6, 31.6, 30.5, 27.7, 20.9, 19.4, 16.8. HRMS (ESI) *m*/*z*: calcd for C~49~H~51~N~2~O~7~^+^, 779.3691; found, 779.3699 M + H^+^.

Compound **6j**, yield 80%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.41--7.17 (m, 17H), 7.02--6.76 (m, 3H), 5.91 (dd, *J* = 2.8, 1.6 Hz, 1H), 5.45 (d, *J* = 4.4 Hz, 1H), 5.52--5.28 (m, 1H, overlapped), 4.84 (br s, 1H), 4.80--4.71 (m, 1H), 3.80 (s, 3H), 2.39 (d, *J* = 8.0 Hz, 2H), 2.23 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.15--1.98 (m, 3H), 1.93--1.83 (m, 2H), 1.82--1.38 (m, 9H), 1.09 (s, 3H), 1.07 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.7, 159.9, 154.8, 139.5, 137.4, 135.7, 130.7, 130.1, 128.8, 128.7, 128.3, 128.2, 128.1, 127.3, 127.2, 126.8, 126.8, 123.0, 113.5, 75.8, 57.6, 55.3, 50.4, 47.3, 38.0, 36.9, 36.9, 35.4, 31.7, 31.7, 30.5, 27.7, 21.0, 19.4, 16.7. HRMS (ESI) *m*/*z*: calcd for C~49~H~52~NO~5~^+^, 734.3840; found, 734.3823 M + H^+^.

Compound **6k**, yield 65%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.24--8.18 (m, 1H), 7.81--7.74 (m, 2H), 7.41--7.20 (m, 12H), 6.91--6.84 (m, 3H), 5.99--5.94 (m, 1H), 5.47 (d, *J* = 4.0 Hz, 1H), 5.52--5.28 (m, 1H, overlapped), 4.86 (br s, 1H), 4.82--4.72 (m, 1H), 3.84 (s, 3H), 2.42 (d, *J* = 8.0 Hz, 2H), 2.34--2.33 (m, 2H), 2.14--2.04 (m, 3H), 1.94--1.58 (m, 10H), 1.11 (s, 3H), 1.05 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.7, 160.0, 150.6, 145.4, 145.3, 139.6, 139.3, 138.3, 135.8, 132.1, 130.2, 129.4, 128.9, 128.8, 128.8, 128.7, 128.3, 128.1, 127.2, 127.1, 127.0, 122.9, 114.4, 113.6, 109.2, 108.8, 75.8, 57.5, 55.4, 50.3, 47.4, 38.0, 36.9, 36.9, 36.9, 35.3, 31.9, 31.6, 30.5, 27.7, 20.9, 19.4, 16.6. HRMS (ESI) *m*/*z*: calcd for C~48~H~50~FN~2~O~5~^+^, 753.3698; found, 753.3683 M + H^+^.

Compound **6l**, yield 57%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.39 (d, *J* = 2.4 Hz, 1H), 7.62 (dd, *J* = 8.0, 2.4 Hz, 1H), 7.41--7.19 (m, 13H), 7.01--6.75 (m, 3H), 6.04--5.99 (m, 1H), 5.46 (d, *J* = 4.0 Hz, 1H), 5.46--5.30 (m, 1H, overlapped), 4.85 (br s, 1H), 4.81--4.71 (m, 1H), 3.82 (s, 3H), 2.40 (d, *J* = 7.6 Hz, 2H), 2.29 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.13--1.97 (m, 4H), 1.93--1.86 (m, 2H), 1.82--1.55 (m, 7H), 1.54--1.44 (m, 1H), 1.10 (s, 3H), 1.04 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 170.0, 160.0, 150.5, 149.6, 147.6, 139.6, 136.6, 135.7, 132.0, 130.7, 130.1, 128.8, 128.7, 128.3, 128.1, 127.2, 123.8, 122.9, 113.6, 75.7, 57.5, 55.4, 50.2, 47.4, 38.0, 36.9, 36.9, 35.2, 31.9, 31.6, 30.4, 27.7, 20.9, 19.4, 16.6. HRMS (ESI) *m*/*z*: calcd for C~48~H~50~ClN~2~O~5~^+^, 769.3403; found, 769.3372 M + H^+^.

Compound **6m**, yield 50%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.21 (d, *J* = 2.0 Hz, 1H), 7.61 (dd, *J* = 8.8, 2.4 Hz, 1H), 7.54--7.20 (m, 12H), 6.87 (d, *J* = 7.2 Hz, 3H), 6.72 (d, *J* = 8.8 Hz, 1H), 5.89 (d, *J* = 1.2 Hz, 1H), 5.47 (d, *J* = 4.4 Hz, 1H), 5.52--5.27 (m, 1H, overlapped), 4.86 (br s, 1H), 4.82--4.71 (m, 1H), 3.96 (s, 3H), 3.84 (s, 3H), 2.42 (d, *J* = 7.8 Hz, 2H), 2.27 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.15--2.00 (m, 3H), 1.95--1.86 (m, 2H), 1.85--1.43 (m, 8H), 1.25--1.15 (m, 1H), 1.11 (s, 3H), 1.04 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.7, 163.2, 160.0, 151.5, 144.3, 139.6, 137.4, 135.8, 130.7, 130.2, 128.9, 128.7, 128.3, 128.1, 127.2, 127.1, 126.4, 123.0, 113.6, 110.4, 75.8, 57.5, 55.4, 53.5, 50.4, 47.3, 38.1, 36.9, 36.9, 35.4, 31.7, 31.7, 30.5, 27.7, 21.0, 19.4, 16.6. HRMS (ESI) *m*/*z*: calcd for C~49~H~53~FN~2~O~6~^+^, 765.3898; found, 765.3905 M + H^+^.

Compound **6n**, yield 78%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.64 (d, *J* = 2.0 Hz, 1H), 8.47 (dd, *J* = 4.8, 1.6 Hz, 1H), 7.44 (dt, *J* = 8.0, 2.0 Hz, 1H), 7.40--7.19 (m, 13H), 7.03--6.73 (m, 3H), 6.04--5.98 (m, 1H), 5.47 (d, *J* = 4.4 Hz, 1H), 5.47--5.31 (m, 1H, overlapped), 4.86 (br s, 1H), 4.81--4.72 (m, 1H), 3.82 (s, 3H), 2.41 (d, *J* = 8.0 Hz, 2H), 2.29 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.15--2.03 (m, 4H), 1.95--1.86 (m, 2H), 1.85--1.47 (m, 8H), 1.11 (s, 3H), 1.07 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.7, 159.9, 151.7, 148.0, 148.0, 139.5, 135.7, 133.8, 133.0, 130.7, 130.1, 129.3, 128.8, 128.7, 128.3, 128.1, 127.2, 123.1, 122.9, 113.5, 75.7, 57.5, 55.3, 50.3, 47.4, 38.0, 36.9, 36.8, 35.2, 31.9, 31.6, 30.4, 27.7, 20.9, 19.3, 16.7. HRMS (ESI) *m*/*z*: calcd for C~48~H~51~N~2~O~5~^+^, 735.3792; found, 735.3802 M + H^+^.

Compound **6o**, yield 56%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.51 (dd, *J* = 4.8, 1.6 Hz, 2H), 7.40--7.20 (m, 15H), 6.85 (d, *J* = 7.2 Hz, 2H), 6.20--6.16 (m, 1H), 5.45 (d, *J* = 4.4 Hz, 1H), 5.50--5.32 (m, 1H, overlapped), 4.84 (br s, 1H), 4.80--4.71 (m, 1H), 3.82 (s, 3H), 2.40 (d, *J* = 7.6 Hz, 2H), 2.28 (ddd, *J* = 16.0, 6.4, 3.2 Hz, 1H), 2.19--2.04 (m, 3H), 1.93--1.85 (m, 2H), 1.85--1.45 (m, 9H), 1.10 (s, 3H), 1.08 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.7, 160.0, 152.6, 149.8, 144.6, 139.6, 135.8, 131.6, 130.8, 130.2, 128.9, 128.7, 128.3, 128.1, 127.2, 122.9, 121.3, 113.6, 75.8, 57.6, 55.4, 50.3, 47.2, 38.0, 36.9, 36.9, 35.2, 31.9, 31.6, 31.6, 30.4, 27.7, 20.9, 19.4, 16.7. HRMS (ESI) *m*/*z*: calcd for C~48~H~51~N~2~O~5~^+^, 735.3792; found, 753.3802 M + H^+^.

Compound **6p**, yield 66%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.53--7.08 (m, 12H), 6.99--6.74 (m, 3H), 5.65 (d, *J* = 1.6 Hz, 1H), 5.45 (d, *J* = 4.4 Hz, 1H), 5.49--5.30 (m, 1H, overlapped), 4.84 (br s, 1H), 4.81--4.70 (m, 1H), 3.81 (s, 3H), 2.39 (d, *J* = 7.6 Hz, 2H), 2.33--2.24 (m, 1H, overlapped), 2.30 (s, 3H, overlapped), 2.17 (s, 3H), 2.14--1.99 (m, 3H), 1.88 (d, *J* = 10.8 Hz, 2H), 1.80--1.35 (m, 9H), 1.07 (s, 3H), 0.83 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.6, 165.6, 159.9, 159.7, 144.2, 139.5, 135.7, 132.4, 130.7, 130.1, 128.8, 128.7, 128.3, 128.1, 127.1, 122.9, 113.5, 112.4, 75.7, 56.7, 55.3, 50.5, 49.4, 38.0, 36.9, 36.9 × 2, 35.3, 32.2, 31.6, 30.8, 27.6, 20.8, 19.3, 16.4, 12.0, 11.2. HRMS (ESI) *m*/*z*: calcd for C~48~H~53~N~2~O~6~^+^, 753.3898; found, 753.3907 M + H^+^.

Compound **6q**, yield 46%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.56--7.07 (m, 14H), 7.04 (d, *J* = 3.6 Hz, 1H), 6.97 (dd, *J* = 5.2, 3.6 Hz, 1H), 6.85 (d, *J* = 7.2 Hz, 2H), 6.05--5.95 (m, 1H), 5.44 (d, *J* = 4.4 Hz, 1H), 5.48--5.28 (m, 1H, overlapped), 4.84 (br s, 1H), 4.80--4.70 (m, 1H), 3.82 (s, 3H), 2.39 (d, *J* = 7.2 Hz, 2H), 2.30--2.19 (m, 2H), 2.13--1.96 (m, 2H), 1.94--1.86 (m, 2H), 1.81--1.51 (m, 8H), 1.22--1.20 (m, 1H), 1.09 (s, 3H), 1.04 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 169.7, 160.0, 148.1, 140.1, 139.6, 135.8, 130.8, 130.2, 128.9, 128.8, 128.4, 128.1, 127.3, 127.2, 126.8, 124.5, 123.6, 123.0, 122.9, 113.6, 75.8, 57.2, 55.4, 50.4, 47.7, 38.1, 36.9, 36.9, 35.5, 31.7, 31.6, 30.5, 30.3, 27.7, 21.1, 19.4, 16.4. HRMS (ESI) *m*/*z*: calcd for C~47~H~50~NO~5~S^+^, 740.9785; found, 740.9802 M + H^+^.

Compound **6r**, yield 60%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.52--7.12 (m, 12H), 6.91 (d, *J* = 8.7 Hz, 2H), 6.53--6.19 (m, 1H), 5.91 (dd, *J* = 3.2, 1.6 Hz, 1H), 5.41 (br s, 1H), 5.32 (s, 1H), 4.52 (d, *J* = 3.6 Hz, 2H), 3.81 (s, 3H), 2.22 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.12--1.97 (m, 4H), 1.89--1.39 (m, 11H), 1.18--1.12 (m, 1H), 1.08 (s, 9H), 1.05 (s, 3H), 1.00 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 160.3, 154.8, 139.8, 137.4, 128.8, 128.5, 128.2, 128.0, 127.3, 126.9, 126.8, 126.5, 122.6, 113.8, 92.0, 80.8, 75.6, 57.7, 55.4, 50.4, 47.3, 36.9, 36.8, 35.4, 31.7, 31.7, 30.5, 28.0 × 3, 22.8, 21.0, 19.3, 16.7. HRMS (ESI) *m*/*z*: calcd for C~47~H~56~NO~6~^+^, 730.4102; found, 730.4121 M + H^+^.

#### General Procedure for the Compounds **7a--7r** {#sec4.1.1.6}

The ester compound **6** (0.05 mmol 1.0 equiv) was added to MeOH (2 mL) and treated with 4-toluene sulfonyl chloride (0.3 mmol, 6.0 equiv). The reaction mixture was stirred at room temperature for 6 h and then diluted with EtOAc. The organic layer was washed with a saturated solution of NaHCO~3~ (aq.) and brine, dried with Na~2~SO~4~, filtered, and concentrated. The crude mixture was purified by silica gel column chromatography (EtOAc/petroleum ether, 1:12) to afford the desired hybrids **7a--7r** as a white solid, yield 60--85%.

Compound **7a**, yield 60%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.78 (d, *J* = 7.6 Hz, 2H), 7.55--7.29 (m, 8H), 7.08 (d, *J* = 9.2 Hz, 1H), 7.00 (s, 2H), 6.89 (s, 1H), 5.88 (s, 1H), 5.79 (d, *J* = 9.2 Hz, 1H), 5.44 (d, *J* = 4.4 Hz 1H), 4.83--4.70 (m, 1H), 4.62 (s, 1H), 3.47 (br s, 1H), 2.51--2.40 (m, 1H), 2.49--2.33 (m, 1H), 2.31 (s, 6H), 2.21 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.13--2.01 (m, 3H), 1.89--1.52 (m, 10H), 1.48--1.42 (m, 1H), 1.09 (s, 3H), 1.06 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 172.5, 166.9, 155.0, 139.7, 138.9, 137.6 × 2, 137.3, 134.4, 131.8, 128.8 × 3, 128.7, 128.6, 128.0, 127.2 × 2, 127.0 × 2, 126.9, 124.7 × 2, 123.0, 76.8, 73.5, 57.7, 54.8, 50.4, 47.3, 38.1, 36.9 × 2, 35.5, 31.7, 31.7, 30.5, 27.6, 21.5 × 2, 21.0, 19.3, 16.8. HRMS (ESI) *m*/*z*: calcd for C~43~H~50~NO~4~^+^, 644.3734; found, 644.3753 M + H^+^.

Compound **7b**, yield 84%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.80--7.72 (d, *J* = 7.2 Hz, 2H), 7.54--7.39 (m, 5H), 7.36 (t, *J* = 7.6 Hz, 2H), 7.32--7.26 (m, 1H), 7.22--7.13 (m, 3H), 7.08--7.01 (m, 2H), 5.88 (d, *J* = 1.2 Hz, 1H), 5.77 (dd, *J* = 9.2, 1.6 Hz, 1H), 5.42 (d, *J* = 4.8 Hz, 1H), 4.79--4.68 (m, 1H), 4.61 (s, 1H), 3.37 (br s, 1H), 2.51--2.40 (m, 1H), 2.39--2.32 (m, 1H), 2.34 (s, 3H), 2.21 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.12--2.00 (m, 3H), 1.90--1.46 (m, 10H), 1.46--1.40 (m, 1H), 1.08 (s, 3H), 1.05 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 172.5, 166.9, 155.0, 139.8, 138.9, 137.7, 137.3, 134.4, 131.9, 128.8, 128.8 × 2, 128.8 × 2, 128.1, 128.0, 127.6, 127.2 × 2, 127.1, 127.0 × 2, 123.9, 123.0, 76.9, 73.5, 57.7, 54.8, 50.4, 47.3, 38.1, 36.9 × 2, 35.5, 31.7, 31.7, 30.6, 27.6, 21.7, 21.0, 19.4, 16.8. HRMS (ESI) *m*/*z*: calcd for C~42~H~48~NO~4~^+^, 630.3578; found, 630.3538 M + H^+^.

Compound **7c**, yield 81%: ^1^H NMR (600 MHz, CDCl~3~): δ 7.76 (d, *J* = 7.2 Hz, 2H), 7.50 (t, *J* = 7.2 Hz, 1H), 7.47--7.40 (m, 4H), 7.36 (t, *J* = 7.2 Hz, 2H), 7.32--7.24 (m, 3H), 7.09 (d, *J* = 7.8 Hz, 2H), 7.01 (d, *J* = 9.0 Hz, 1H), 5.86 (d, *J* = 0.6 Hz, 1H), 5.76 (dd, *J* = 9.0, 1.2 Hz, 1H), 5.44--5.39 (m, 1H), 4.77--4.70 (m, 1H), 4.61 (s, 1H), 3.34 (br s, 1H), 2.47--2.41 (m, 1H), 2.37--2.34 (m, 1H), 2.33 (s, 3H), 2.20 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.09--1.98 (m, 3H), 1.87--1.80 (m, 2H), 1.79--1.71 (m, 1H), 1.71--1.50 (m, 6H), 1.48--1.41 (m, 1H), 1.14--1.09 (m, 1H), 1.08 (s, 3H), 1.04 (s, 3H). ^13^C NMR (150 MHz, CDCl~3~): δ 172.5, 166.9, 154.7, 139.7, 138.9, 136.5, 134.5, 134.4, 131.9, 129.0 × 2, 128.8 × 2, 128.8 × 2, 128.0, 127.2 × 2, 127.0 × 2, 126.7 × 2, 126.5, 123.0, 76.9, 73.5, 57.7, 54.8, 50.4, 47.2, 38.1, 36.9 × 2, 35.5, 31.7, 31.7, 30.5, 27.6, 21.3, 21.0, 19.4, 16.7. HRMS (ESI) *m*/*z*: calcd for C~42~H~48~NO~4~^+^, 630.3578; found, 630.3538 M + H^+^.

Compound **7d**, yield 65%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.80--7.70 (m, 5H), 7.50--7.39 (m, 5H), 7.38--7.33 (m, 2H), 7.32--7.26 (m, 1H), 7.06 (d, *J* = 9.2 Hz, 1H), 6.10 (s, 1H), 5.78 (dd, *J* = 9.2, 1.6 Hz, 1H), 5.42 (d, *J* = 4.8 Hz, 1H), 4.80--4.68 (m, 1H), 4.61 (s, 1H), 3.45 (br s, 1H), 2.50--2.40 (m, 1H), 2.40--2.33 (m, 1H), 2.29 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.13--1.99 (m, 3H), 1.89--1.54 (m, 10H), 1.53--1.46 (m, 1H), 1.08 (s, 3H), 1.07 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 172.5, 166.9, 152.5, 139.8, 139.4, 138.9, 134.4, 131.8, 131.7, 131.4, 131.3, 128.8 × 2, 128.8 × 2, 128.0, 127.2 × 2, 127.0 × 2, 126.6, 126.6, 124.9, 122.7, 122.2, 120.4, 76.7, 73.5, 57.7, 54.8, 50.3, 47.5, 38.1, 36.9 × 2, 35.2, 31.9, 31.6, 30.4, 27.5, 20.9, 19.4, 16.8. HRMS (ESI) *m*/*z*: calcd for C~43~H~44~F~6~NO~4~^+^, 752.3169; found, 752.3142 M + H^+^.

Compound **7e**, yield 84%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.79--7.72 (d, *J* = 7.2 Hz, 2H), 7.53 (m, 3H), 7.46 (m, 6H), 7.39--7.33 (m, 2H), 7.32--7.26 (m, 1H), 7.02 (d, *J* = 9.2 Hz, 1H), 6.01 (d, *J* = 1.2 Hz, 1H), 5.78 (dd, *J* = 9.2, 1.6 Hz, 1H), 5.42 (d, *J* = 4.8 Hz, 1H), 4.80--4.69 (m, 1H), 4.62 (d, *J* = 2.0 Hz, 1H), 3.35 (br s, 1H), 2.50--2.40 (m, 1H), 2.39--2.32 (m, 1H), 2.25 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.11--2.01 (m, 3H), 1.88--1.52 (m, 10H), 1.50--1.42 (m, 1H), 1.08 (s, 3H), 1.06 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 172.5, 166.9, 153.8, 141.0, 141.0, 139.8, 138.9, 134.4, 131.9 × 2, 129.7, 128.8 × 2, 128.8 × 2, 128.0, 127.2 × 2, 127.0 × 2, 126.9 × 2, 125.2, 125.2, 122.9, 76.8, 73.5, 57.7, 54.8, 50.4, 47.4, 38.1, 36.9 × 2, 35.3, 31.9, 31.6, 30.5, 27.6, 20.9, 19.4, 16.8. HRMS (ESI) *m*/*z*: calcd for C~42~H~45~F~3~NO~4~^+^, 684.3295; found, 684.3287 M + H^+^.

Compound **7f**, yield 77%: ^1^H NMR (600 MHz, CDCl~3~): δ 7.76 (d, *J* = 7.2 Hz, 2H), 7.51 (t, *J* = 7.2 Hz, 1H), 7.47--7.44 (m, 3H), 7.37 (t, *J* = 7.2 Hz, 2H), 7.32--7.23 (m, 6H, overlapped), 6.99 (d, *J* = 9.0 Hz, 1H), 5.90 (s, 1H), 5.78 (d, *J* = 9.0 Hz, 1H), 5.44--5.41 (m, 1H), 4.78--4.71 (m, 1H), 4.63--4.61 (m, 1H), 3.28 (d, *J* = 3.0 Hz, 1H), 2.49--2.41 (m, 1H), 2.38--2.32 (m, 1H), 2.25--2.20 (m, 1H), 2.06--1.99 (m, 3H), 1.88--1.80 (m, 2H), 1.79--1.58 (m, 7H), 1.47--1.40 (m, 1H), 1.15--1.09 (m, 1H), 1.08 (s, 3H), 1.03 (s, 3H). ^13^C NMR (150 MHz, CDCl~3~): δ 172.5, 166.9, 153.8, 139.8, 138.9, 135.9, 134.4, 132.6, 131.9, 128.9 × 2, 128.8 × 2, 128.4 × 2, 128.1 × 2, 128.0, 128.0, 127.2 × 2, 127.0 × 2, 123.0, 76.9, 73.5, 57.7, 54.8, 50.4, 47.3, 38.1, 36.9 × 2, 35.4, 31.8, 31.7, 30.5, 27.6, 21.0, 19.4, 16.7. HRMS (ESI) *m*/*z*: calcd for C~41~H~45~ClNO~4~^+^, 650.3032; found, 650.3013 M + H^+^.

Compound **7g**, yield 62%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.76 (d, *J* = 7.2 Hz, 2H), 7.54--7.39 (m, 5H), 7.36 (t, *J* = 7.2 Hz, 2H), 7.32--7.26 (m, 1H), 7.21 (t, *J* = 8.0 Hz, 1H), 7.04 (d, *J* = 9.2 Hz, 1H), 6.96 (d, *J* = 7.6 Hz, 1H), 6.91 (s, 1H), 6.78 (dd, *J* = 8.0, 2.4 Hz, 1H), 5.92 (s, 1H), 5.84--5.72 (dd, *J* = 9.2, 1.6 Hz, 1H), 5.42 (d, *J* = 4.8 Hz, 1H), 4.80--4.67 (m, 1H), 4.61 (s, 1H), 3.80 (s, 3H), 3.40 (br s, 1H), 2.50--2.39 (m, 1H), 2.39--2.30 (m, 1H), 2.26--2.15 (m, 1H), 2.13--1.96 (m, 3H), 1.88--1.78 (m, 2H), 1.78--1.43 (m, 8H), 1.43--1.32 (m, 1H), 1.07 (s, 3H), 1.05 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 172.5, 166.9, 159.4, 154.7, 139.7, 138.9, 138.8, 134.4, 131.8, 129.1, 128.8 × 2, 128.8 × 2, 128.0, 127.6, 127.2 × 2, 127.0 × 2, 123.0, 119.4, 112.7, 112.0, 76.8, 73.5, 57.7, 55.3, 54.8, 50.4, 47.3, 38.1, 36.9 × 2, 35.4, 31.7 × 2, 30.5, 27.6, 21.0, 19.4, 16.8. HRMS (ESI) *m*/*z*: calcd for C~42~H~48~NO~5~^+^, 646.3527; found, 646.3546 M + H^+^.

Compound **7h**, yield 70%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.10--8.04 (m, 1H), 7.85--7.78 (m, 1H), 7.78--7.72 (m, 3H), 7.53--7.39 (m, 8H), 7.39--7.31 (m, 2H), 7.31--7.25 (m, 2H), 7.08 (d, *J* = 9.2 Hz, 1H), 5.81--5.73 (m, 2H), 5.45 (d, *J* = 4.8 Hz, 1H), 4.81--4.67 (m, 1H), 4.61 (dd, *J* = 3.2, 2.4 Hz, 1H), 3.48 (d, *J* = 3.6 Hz, 1H), 2.51--2.34 (m, 3H), 2.27--2.07 (m, 2H), 1.89--1.39 (m, 11H), 1.14--1.09 (m, 1H), 1.06 (s, 3H), 1.00 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 172.5, 166.9, 152.8, 139.8, 138.9, 136.0, 134.3, 133.8, 132.9, 131.8, 129.7, 128.8 × 2, 128.8 × 2, 128.2, 127.9, 127.2 × 2, 127.1, 127.0 × 2, 126.8, 125.6 × 2, 125.5, 125.0, 123.0, 76.8, 73.5, 57.5, 54.8, 50.6, 49.6, 38.1, 36.9, 36.9, 35.1, 32.4, 31.9, 31.0, 27.5, 21.9, 19.4, 16.4. HRMS (ESI) *m*/*z*: calcd for C~45~H~48~NO~4~^+^, 666.3578; found, 666.3617 M + H^+^.

Compound **7i**, yield 75%: ^1^H NMR (600 MHz, CDCl~3~): δ 8.23 (t, *J* = 1.8 Hz, 1H), 8.07 (ddd, *J* = 7.8, 2.4, 0.6 Hz, 1H), 7.79 (m, 2H), 7.67 (dt, *J* = 7.8, 1.2 Hz, 1H), 7.53--7.29 (m, 1H), 7.47--7.42 (m, 5H), 7.38--7.35 (m, 2H), 7.30 (t, *J* = 7.2 Hz, 1H), 7.00 (d, *J* = 9.0 Hz, 1H), 6.07 (dd, *J* = 3.6, 1.8 Hz, 1H), 5.80 (dd, *J* = 9.6, 2.4 Hz, 1H), 5.44--5.41 (m, 1H), 4.78--4.71 (m, 1H), 4.62 (d, *J* = 1.8 Hz, 1H), 3.32 (s, 1H), 2.50--2.40 (m, 1H), 2.37 (ddd, *J* = 13.2, 5.4, 2.4 Hz, 1H), 2.28 (ddd, *J* = 16.2, 6.6, 3.6 Hz, 1H), 2.12--2.04 (m, 3H), 1.88--1.81 (m, 2H), 1.78 (qd, *J* = 10.8, 4.8 Hz, 1H), 1.72--1.55 (m, 7H), 1.48 (td, *J* = 12.0, 5.4 Hz, 1H), 1.09 (s, 3H), 1.08 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 172.5, 166.9, 152.9, 148.4, 139.8, 139.0, 138.9, 134.4, 132.7, 131.9, 130.4, 129.1, 128.8 × 2, 128.8 × 2, 128.0, 127.2 × 2, 127.0 × 2, 122.8, 121.6, 121.5, 76.8, 73.5, 57.7, 54.8, 50.3, 47.4, 38.1, 36.9 × 2, 35.3, 31.9, 31.6, 30.5, 27.6, 20.9, 19.4, 16.8. HRMS (ESI) *m*/*z*: calcd for C~41~H~45~N~2~O~6~^+^, 661.3272; found, 661.3248 M + H^+^.

Compound **7j**, yield 86%: ^1^H NMR (600 MHz, CDCl~3~): δ 7.78--7.73 (m, 2H), 7.51 (t, *J* = 7.2 Hz, 1H), 7.48--7.41 (m, 4H), 7.39--7.34 (m, 4H), 7.33--7.27 (m, 3H), 7.22 (t, *J* = 7.2 Hz, 1H), 7.01 (d, *J* = 9.6 Hz, 1H), 5.91 (dd, *J* = 3.0, 1.8 Hz, 1H), 5.78 (dd, *J* = 9.6, 1.8 Hz, 1H), 5.45--5.39 (m, 1H), 4.79--4.71 (m, 1H), 4.62 (s, 1H), 3.31 (d, *J* = 3.0 Hz, 1H), 2.49--2.41 (m, 1H), 2.37 (ddd, *J* = 12.6, 4.8, 1.8 Hz, 1H), 2.22 (ddd, *J* = 15.6, 6.6, 3.0 Hz, 1H), 2.11--2.02 (m, 3H), 1.88--1.81 (m, 2H), 1.77 (qd, *J* = 10.8, 4.8 Hz, 1H), 1.72--1.53 (m, 7H), 1.47 (td, *J* = 12.0, 6.0 Hz, 1H), 1.09 (s, 3H), 1.06 (s, 3H). ^13^C NMR (150 MHz, CDCl~3~): δ 172.5, 166.9, 154.9, 139.8, 138.9, 137.4, 134.4, 131.9, 128.8 × 2, 128.8 × 2, 128.2 × 2, 128.0, 127.3, 127.2 × 2, 127.0 × 2, 126.9, 126.8 × 2, 123.0, 77.0, 73.5, 57.7, 54.8, 50.4, 47.3, 38.1, 36.9 × 2, 35.4, 31.7, 31.7, 30.6, 27.6, 21.0, 19.4, 16.8. HRMS (ESI) *m*/*z*: calcd for C~41~H~46~NO~4~^+^, 616.3421; found, 616.3444 M + H^+^.

Compound **7k**, yield 69%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.18 (d, *J* = 2.0 Hz, 1H), 7.81--7.69 (m, 3H), 7.53--7.28 (m, 8H), 7.06 (d, *J* = 9.2 Hz, 1H), 6.86 (dd, *J* = 8.4, 2.8 Hz, 1H), 5.94 (s, 1H), 5.77 (dd, *J* = 9.2, 1.6 Hz, 1H), 5.42 (d, *J* = 4.8 Hz, 1H), 4.80--4.67 (m, 1H), 4.61 (dd, *J* = 2.8, 2.4 Hz, 1H), 3.48 (d, *J* = 3.6 Hz, 1H), 2.50--2.40 (m, 1H), 2.39--2.32 (m, 1H), 2.26 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.07--1.93 (m, 3H), 1.89--1.50 (m, 10H), 1.48--1.40 (td, *J* = 12.0, 5.2 Hz, 1H), 1.08 (s, 3H), 1.01 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 172.5, 166.9, 163.8/161.5, 150.6, 145.4/145.3, 139.8, 139.3/139.2, 138.9, 134.4, 131.8, 131.1/131.0, 129.3, 128.8 × 2, 128.8 × 2, 128.0, 127.2 × 2, 127.0 × 2, 122.8, 109.2/108.8, 76.7, 73.5, 57.5, 54.8, 50.3, 47.4, 38.1, 36.9 × 2, 35.3, 31.8, 31.6, 30.5, 27.5, 20.9, 19.4, 16.6. HRMS (ESI) *m*/*z*: calcd for C~40~H~44~FN~2~O~4~^+^, 635.3280; found, 635.3283 M + H^+^.

Compound **7l**, yield 66%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.37 (d, *J* = 2.4 Hz, 1H), 7.79--7.73 (m, 2H), 7.62--7.57 (m, 1H), 7.53--7.40 (m, 5H), 7.39--7.33 (m, 2H), 7.32--7.24 (m, 2H), 7.02 (d, *J* = 9.2 Hz, 1H), 6.03--5.97 (m, 1H), 5.78 (dd, *J* = 9.2, 2.0 Hz, 1H), 5.44--5.40 (m, 1H), 4.79--4.69 (m, 1H), 4.62 (s, 1H), 3.37 (s, 1H), 2.49--2.39 (m, 1H), 2.39--2.32 (m, 1H), 2.29--2.22 (m, 1H), 2.02 (m, 3H), 1.89--1.79 (m, 2H), 1.79--1.56 (m, 8H), 1.49--1.41 (m, 1H), 1.08 (s, 3H), 1.02 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 172.5, 166.9, 150.6, 149.6, 147.7, 139.8, 138.9, 136.7, 134.4, 132.0, 131.9, 130.1, 128.8 × 2, 128.8 × 2, 128.0, 127.2 × 2, 127.0 × 2, 123.8, 122.8, 76.8, 73.5, 57.5, 54.8, 50.3, 47.5, 38.1, 36.9 × 2, 35.2, 32.0, 31.6, 30.5, 27.5, 20.9, 19.4, 16.7. HRMS (ESI) *m*/*z*: calcd for C~40~H~44~ClN~2~O~4~^+^, 651.2984; found, 651.3030 M + H^+^.

Compound **7m**, yield 75%: ^1^H NMR (400 MHz, CDCl~3~): δ 8.17 (d, *J* = 2.4 Hz, 1H), 7.80--7.71 (m, 2H), 7.57 (dd, *J* = 8.8, 2.4 Hz, 1H), 7.53--7.40 (m, 5H), 7.37 (t, *J* = 7.2 Hz, 2H), 7.33--7.27 (m, 1H), 7.02 (d, *J* = 9.2 Hz, 1H), 6.69 (d, *J* = 8.4 Hz, 1H), 5.85 (dd *J* = 2.8, 1.6 Hz, 1H), 5.77 (dd, *J* = 9.6, 2.0 Hz, 1H), 5.42 (d, *J* = 5.2 Hz, 1H), 4.79--4.68 (m, 1H), 4.61 (s, 1H), 3.93 (s, 3H), 3.35 (br s, 1H), 2.50--2.39 (m, 1H), 2.39--2.30 (m, 1H), 2.22 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.10--1.98 (m, 3H), 1.88--1.79 (m, 2H), 1.78--1.52 (m, 8H), 1.51--1.43 (m, 1H), 1.08 (s, 3H), 1.00 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 172.5, 166.9, 163.2, 151.5, 144.4, 139.8, 138.9, 137.4, 134.4, 131.9, 128.8 × 2, 128.8 × 2, 128.0, 127.2 × 2, 127.1, 127.0 × 2, 126.4, 122.9, 110.4, 76.8, 73.5, 57.5, 54.8, 53.5, 50.4, 47.3, 38.1, 36.9 × 2, 35.4, 31.7, 31.7, 30.5, 27.6, 21.0, 19.4, 16.6. HRMS (ESI) *m*/*z*: calcd for C~41~H~47~N~2~O~5~^+^, 647.3479; found, 647.3480 M + H^+^.

Compound **7n**, yield 76%: ^1^H NMR (600 MHz, CDCl~3~): δ 8.60 (s, 1H), 8.44 (d, *J* = 3.6 Hz, 1H), 7.76 (d, *J* = 7.2 Hz, 2H), 7.64 (d, *J* = 8.4 Hz, 1H), 7.50 (t, *J* = 7.2 Hz, 1H), 7.47--7.41 (m, 4H), 7.36 (t, *J* = 7.8 Hz, 2H), 7.30 (t, *J* = 7.8 Hz, 1H), 7.22 (dd, *J* = 7.8, 5.4 Hz, 1H), 7.04 (d, *J* = 9.0 Hz, 1H), 5.99 (s, 1H), 5.77 (dd, *J* = 9.0, 1.2 Hz, 1H), 5.44--5.40 (m, 1H), 4.78--4.70 (m, 1H), 4.62 (d, *J* = 1.8 Hz, 1H), 2.48--2.41 (m, 1H), 2.36 (ddd, *J* = 13.2, 4.8, 1.2 Hz, 1H), 2.26 (ddd, *J* = 15.6, 6.6, 3.6 Hz, 1H), 2.09--2.00 (m, 3H), 1.87--1.81 (m, 2H), 1.76 (qd, *J* = 9.0, 1.2 Hz, 1H), 1.71--1.53 (m, 7H), 1.47 (dt, *J* = 12.0, 5.4 Hz, 1H), 1.08 (s, 3H), 1.03 (s, 3H). ^13^C NMR (150 MHz, CDCl~3~): δ 172.5, 166.9, 151.7, 148.0, 147.9, 139.8, 139.0, 134.4, 133.9, 133.1, 131.8, 129.4, 128.8 × 2, 128.8 × 2, 128.0, 127.2 × 2, 127.0 × 2, 123.2, 122.9, 76.7, 73.5, 57.6, 54.9, 50.3, 47.5, 38.1, 36.9 × 2, 35.3, 31.9, 31.7, 30.5, 27.6, 20.9, 19.4, 16.7. HRMS (ESI) *m*/*z*: calcd for C~40~H~45~N~2~O~4~^+^, 617.3374; found, 617.3398 M + H^+^.

Compound **7o**, yield 84%: ^1^H NMR (600 MHz, CDCl~3~): δ 8.48 (d, *J* = 6.0 Hz, 2H), 7.78--7.71 (m, 2H), 7.51 (t, *J* = 7.2 Hz, 1H), 7.48--7.41 (m, 4H), 7.37 (t, *J* = 7.2 Hz, 2H), 7.30 (t, *J* = 7.8 Hz, 1H), 7.24 (d, *J* = 6.6 Hz, 2H), 7.02 (d, *J* = 9.6 Hz, 1H), 6.16 (dd, *J* = 3.0, 1.8 Hz, 1H), 5.77 (dd, *J* = 9.6, 1.8 Hz, 1H), 5.44--5.40 (m, 1H), 4.77--4.71 (m, 1H), 4.62 (d, *J* = 2.4 Hz, 1H), 2.48--2.40 (m, 1H), 2.36 (ddd, *J* = 13.2, 4.8, 1.2 Hz, 1H), 2.26 (ddd, *J* = 13.2, 5.4, 1.8 Hz, 1H), 2.13--2.03 (m, 3H), 1.87--1.80 (m, 2H), 1.76 (qd, *J* = 10.8, 5.4, 1H), 1.71--1.61 (m, 5H), 1.61--1.53 (m, 2H), 1.48--1.41 (m, 1H), 1.09 (s, 3H), 1.07 (s, 3H). ^13^C NMR (150 MHz, CDCl~3~): δ 172.5, 166.9, 152.6, 149.8 × 2, 144.7, 139.8, 138.9, 134.4, 131.9, 131.6, 128.8 × 2, 128.8 × 2, 128.0, 127.2 × 2, 127.0 × 2, 122.8, 121.3 × 2, 76.7, 73.5, 57.6, 54.8, 50.3, 47.2, 38.1, 36.9 × 2, 35.2, 31.9, 31.6, 30.4, 27.6, 20.9, 19.4, 16.7. HRMS (ESI) *m*/*z*: calcd for C~40~H~45~N~2~O~4~^+^, 617.3374; found, 617.3348 M + H^+^.

Compound **7p**, yield 72%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.79--7.72 (m, 2H), 7.53--7.38 (m, 5H), 7.35 (t, *J* = 7.2 Hz, 2H), 7.32--7.25 (m, 1H) 7.07 (dd, *J* = 9.2, 3.6 Hz, 1H), 5.79--5.73 (m, 1H), 5.64 (d, *J* = 1.6 Hz, 1H), 5.42 (d, *J* = 5.2 Hz, 1H), 4.79--4.68 (m, 1H), 4.61 (s, 1H), 3.49 (br s, 1H), 2.49--2.39 (m, 1H), 2.39--2.31 (m, 1H), 2.31--2.20 (m, 1H, overlapped), 2.29 (s, 3H, overlapped), 2.15 (s, 3H), 2.10--1.98 (m, 3H), 1.88--1.75 (m, 3H), 1.74--1.62 (m, 3H), 1.62--1.34 (m, 5H), 1.06 (s, 3H), 0.82 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 172.5, 166.9, 165.7, 159.8, 144.3, 139.8, 138.9, 134.4, 132.4, 131.8, 128.8 × 2, 128.8 × 2, 127.9, 127.2 × 2, 127.0 × 2, 122.8, 112.4, 76.7, 73.5, 56.8, 54.8, 50.6, 49.4, 38.1, 36.9, 36.9, 35.3, 32.2, 31.7, 30.8, 27.5, 20.8, 19.4, 16.4, 12.0, 11.2. HRMS (ESI) *m*/*z*: calcd for C~40~H~47~N~2~O~5~^+^, 635.3479; found, 635.3438 M + H^+^.

Compound **7q**, yield 78%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.79--7.72 (m, 2H), 7.53--7.39 (m, 5H), 7.36 (t, *J* = 7.2 Hz, 2H), 7.32--7.26 (m, 1H), 7.13 (d, *J* = 5.2 Hz, 1H), 7.07--7.00 (m, 2H), 6.96 (dd, *J* = 5.2, 3.6 Hz, 1H), 5.97 (dd, *J* = 5.2, 2.0 Hz, 1H), 5.41 (d, *J* = 5.2 Hz, 1H), 4.79--4.68 (m, 1H), 4.61 (s, 1H), 3.39 (s, 1H), 2.49--2.39 (m, 1H), 2.39--2.31 (m, 1H), 2.27--2.17 (m, 2H), 2.09--1.96 (m, 2H), 1.91--1.77 (m, 2H), 1.77--1.46 (m, 8H), 1.16--1.05 (m, 1H, overlapped), 1.08 (s, 3H), 1.02 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 172.5, 166.9, 148.1, 140.1, 139.7, 138.9, 134.4, 131.9, 128.8 × 2, 128.8 × 2, 128.0, 127.3, 127.2 × 2, 127.0 × 2, 126.7, 123.6, 122.9 × 2, 76.8, 73.5, 57.2, 54.8, 50.4, 47.7, 38.1, 36.9 × 2, 35.5, 31.7, 31.6, 30.5, 27.6, 21.0, 19.4, 16.4. HRMS (ESI) *m*/*z*: calcd for C~39~H~44~NO~4~S^+^, 622.2986; found, 622.2986 M + H^+^.

Compound **7r**, yield 68%: ^1^H NMR (400 MHz, CDCl~3~): δ 7.41--7.19 (m, 10H), 5.91 (s, 1H), 5.51--5.37 (m, 2H), 5.25 (d, *J* = 9.2 Hz, 1H), 4.80--4.67 (m, 1H), 4.45 (s, 1H), 3.22 (br s, 1H), 2.45--2.41 (m, 1H), 2.41--2.31 (m, 1H), 2.23 (ddd, *J* = 15.6, 6.4, 3.2 Hz, 1H), 2.14--1.99 (m, 3H), 1.97--1.81 (m, 2H), 1.81--1.53 (m, 8H), 1.53--1.46 (m, 1H), 1.40 (s, 9H), 1.10 (s, 3H), 1.06 (s, 3H). ^13^C NMR (100 MHz, CDCl~3~): δ 172.5, 155.1, 154.9, 139.8, 139.6, 137.4, 128.72, 128.2 × 2, 127.8, 127.3, 126.9, 126.8 × 2, 126.8, 126.8, 123.0, 79.9, 76.7, 73.8, 57.7, 56.0, 50.5, 47.3, 38.1, 37.0, 36.9 × 2, 35.5, 31.7, 30.6, 28.4 × 3, 27.5, 21.0, 19.4, 16.8. HRMS (ESI) *m*/*z*: calcd for C~39~H~50~NO~5~^+^, 612.3684; found, 612.3702 M + H^+^.

Biology {#sec4.2}
-------

### Materials {#sec4.2.1}

MTT (M2128) was purchased from Sigma-Aldrich (St. Louis, Mo, USA). The HepG-2 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and incubated with 5% CO~2~.

### MTT Assay {#sec4.2.2}

MTT assay was employed primarily for determination. The in vitro inhibitory activities of eighteen hybrids on HepG-2 cells were evaluated. HepG-2 cells were seeded at a density of 5 × 10^3^/well in a 96-well plate for 24 h and then treated with different concentrations of compounds dissolved in 100% dimethyl sulfoxide (DMSO) for 24 h, with the final DMSO concentrations lower than 0.1%. Control cells were treated with Taxol containing 0.1% DMSO. DMSO served as a negative control. Then, 10 μL of MTT (5 mg/mL) was added into each well and incubated for another 4 h. The purple formazan crystals were dissolved in 100 μL of DMSO and the absorbance was detected at 570 nm using a microplate reader (Thermo MK3, USA).

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.0c00558](https://pubs.acs.org/doi/10.1021/acsomega.0c00558?goto=supporting-info).^1^H and ^13^C NMR spectra for all the new compounds ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c00558/suppl_file/ao0c00558_si_001.pdf))
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